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ABSTRACT  
In order to identify and define the fluid dynamic characteristics of 
primary importance in quantifying heart valve performance, GTRI has carried 
out a paper study of this subject under contract with the FDA. Where pos-
sible these fluid dynamic characteristics have been related to valve 
hemodynamics and clinical complications such as hemolysis, thromembolism, 
thrombus formation, tissue overgrowth and other valve dysfunctions. 
This Phase I study is intended to provide a better understanding for 
the need to establish in vitro flow testing guidelines which encompass 
state-cf-the-art instrumentation and methodology. The study indicates 
very clearly that there is more to the in vitro and in vivo fluid dynamic 
performance of a heart valve prosthesis other than pressure drop and 
regurgitation. The study also indicates the need for good clinical follow 
up data on heart valve recipients, analysis of sub-lethal and/or lethal 
damage to blood components and endothelial tissue, and detailed pathologic 
studies on recovered (at surgery and/or autopsy) valve prostheses. 
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III. CONCLUSIONS 
Following the collection, analysis, and interpretation of the in vivo  
and in vitro information and data pertaining to the current state of the art 
in respect to the safety and performance of prosthetic heart valves (mechanical 
and tissue), Georgia Tech concludes that: 
(1) At present we do not have an ideal prosthetic heart valve. During 
the past 20 years manufacturers have developed and produced various designs 
of prosthetic heart valves, some of which perform satisfactorily when implanted 
surgically in patients suffering from valvular heart disease. Other designs 
have had to be removed from the open market due to lack of adequate safety and 
efficiency. 
(2) There is a lack of in vivo clinical and in vitro fluid dynamic data 
and information on all designs of prosthetic heart valves in current clinical 
use. The lack of good quality clinical information and data on some of the 
older valve types is surprising. 
(3) Good long term clinical follow up data exists only for the following 
valves types studied: (i) Starr-Edwards ball valves, (ii) Bjork-Shiley 
tilting disc valve, (iii) Lillehei-Kaster tilting disc valve, and (iv) Hancock 
porcine valve. 
(4) There is a lack of good detailed pathologic studies performed on heart 
valves recovered at surgery and/or autopsy. The lack of such studies will hinder 
the progress and development of not only better heart valve prostheses but also 
other future artificial devices such as left ventricular assist devices and the 
total artificial heart. 
(5) The caliber and quantitative nature of the in vitro fluid dynamic studies 
has improved a great deal during the past five to six years. There are, however, 
many pieces of information missing which would give us a better understanding of 
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some of the clinical problems observed with prosthetic heart valves. 
(6) There seems to be a lack of collaboration between the in vitro  
investigator and the physician (cardiologist and/or cardiovascular surgeon). 
Therefore, there are very few articles that attempt to relate specific in 
vitro flow characteristics to clinical performance and complications. The 
lack of such information will impede the progress of prosthetic heart valves 
and similar cardiovascular devices. 
(7) The available in vivo hemodynamic and in vitro pressure drop results 
from all valves when analyzed in a combined overall manner indicate that the 
prostheses studied could be arranged in the following order of decreasing steno-
ticity: (i) caged disc valves designs; (ii) caged ball valves, Lillehei-Kaster 
tilting disc valve and porcine valves; (iii) Bjork-Shiley tilting disc valve and 
lonescu-Shiley pericardial valve; (iv) Hall-Kaster tilting disc valve; (v) St. Jude 
bi-leaflet valve. 
(8) In terms of regurgitation, in vitro studies indicate that the values 
can be arranged in the following order increasing regurgitation: (i) porcine 
valves; (ii) lonescu-Shiley pericardial valve; (iii) Starr-Edwards and Braunwald-
Cutter ball valves, and Kay-Shiley and Beall disc valves; (iv) Smeloff-Cutter 
ball valve, Bjork-Shiley, Lillehei-Kaster, Hall-Kaster tilting disc valves, and 
St. Jude bi-leaflet valve. 
(9) All prosthetic valves (mechanical and tissue) in current clinical use 
cause sub-lethal and/or lethal damage to blood elements such as red cells and 
platelets. The shear fields created by the valves are all capable of causing 
such damage. Sub-lethal damage to red cells could in time lead to mild hemolysis. 
Similarly, sub-lethal damage to platelets could over a period of time lead to 
thromboemboli and complications. 
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(10) All peripheral flow type valves cause damage to the endothelial 
lining of the proximal ascending aorta. This is directly related to the 
elevated wall shear stresses in the immediate downstream vicinity of these valves. 
They may also cause sub-lethal and/or lethal damage to the ventricular wall. 
Other mechanical designs and tissue bioprostheses could cause sub-lethal and/ 
or lethal damage to the endothelial lining of the aortic wall. The jet type 
flow from the tissue valves could cause damage to the ventricular wall. 
Depending on the orientation of the valve the flow in the major orifice region 
of the tilting disc valve could also cause damage to the ventricular wall. 
(12) All prosthetic valves in current clinical use cause hemolysis and 
thromboembolic complications and are prone to the problems of thrombus formation 
and excess tissue growth on the valve superstructure. 
(12) In many cases the hemolysis caused by the prosthesis is mild or 
moderate and is generally compensated for quite adequately by the bone-marrow. 
Cloth covering on the valve superstructure (such as with the Starr-Edwards and 
Beall valves) will lead to an increase in hemolysis depending on the structure 
and surface characteristics of the fabric. Hemolysis, however, mild is not 
innocuous. It is the forerunner in one of the proposed mechanisms for platelet 
aggregation and coagulation which could lead to the formation of thromboemboli. 
(13) Mechanical valves in current clinical use have TEC rates of about 
2 to 8% per pt yr for patients on anticoagulation therapy. Tissue valves have 
TEC rates of about 2 to 5.5% per pt yr without long term anticoagulation therapy. 
(14) Thrombus formation and tissue overgrowth on the valve superstructure 
are most often found in regions of flow stasis, very low flow and shear, and flow 
separation. 
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(15) Mechanical damage to the blood elements as well as to the 
endothelial tissue of the adjacent vessel wall, may in addition trigger 
complex biochemical reactions which could lead to the excess fibrous tissue 
overgrowth observed on recovered valves. 
(lb) Tissue valves are prone to calcification especially in children. 
Calcification mainly occurs on the outflow surface of the leaflet. Therefore, 
it is ver:,- probaLle that the relatively stiff nature of the current leaflets, 
together with the region flow separation between outflow surface of the leaflets 
and vessel wall, could lead to the deposition of thrombotic and calcific 
material on the leaflets. 
IV. RECOMMENDATIONS  
1. Set up a national registry for prosthetic heart valves immediately. Detailed 
pathologic, and non-destructive and destructive engineering studies should 
be conducted on recovered valves, under the auspicies of the registry. At 
the time of valve implantation surgery, patients should be requested to sign 
a release so that the valve or valves may be recovered for scientific 
purposes at death. Current implant retrieval programs conducted by some 
of the manufacturers do not facilitate free transfer of information among 
the medical and scientific communities. It seems as if those valve prostheses 
disappear from the public domain. 
2. An educational program should be established for patients which provides 
reliable and accurate scientific information regarding the current 
status of various heart valve prostheses, their uses and limitations, and 
potential problems. 
3. Require good clinical follow up data on all designs of valve prostheses. 
Such clinical follow up should include more detailed and sensitive tests to 
study blood component damage. For example, half-life studies should be 
conducted on tagged red cells and platelets. The filterability of the red 
cells in micropores should also be studied. 	It may be necessary in the 
initial stages to sponsor such studies at a few major medical centers. 
4. Standardized methodology should be established for reporting hemodvnamic, 
hemolysis and TEC data. Such an effort would require the cooperation of 
the American Heart Association, American College of Cardiology and American 
Association of Thoracic Surgeons. 
5. Guidelines for the in vitro fluid dynamic testing of heart valves should 
be set up immediately. Such guidelines should include not only pressure drop, 
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regurgitation and flow visualization studies, but also velocity and shear 
stress measurements in the immediate vicinity of the valve. Such measure-
ments are necessary to understand the clinically observed problems of 
hemolysis, thromboembolism, thrombus formation, excess tissue overgrowth 
and damage to the endothelial lining of vessel walls. Fluid dynamic 
studies should be conducted under steady and pulsatile flow conditions. 
6. An inter-laboratory comparison program for new and recovered heart valve 
prostheses should be established, under the auspicies of the Bureau of 
Medical Devices Laboratory. 
7. A task by task program for the fluid dynamic evaluation of prosthetic 
heart valves in current clinical use should be established. Such studies 
should be jointly supported by manufacturers and the FDA. 
8. Further studies should be conducted to elucidate the answers to the 
problems of sub-lethal and/or lethal damage to all blood elements and 
endothelial tissue. 
9. A national or international conference on prosthetic heart valves should 
be held within the next year or two. The last such conference was held in 
1969. The conference participants should include cardiovascular surgeons, 
cardiologists, cardiovascular pathologists, manufacturers and BND personnel. 
10. Improve communication between the physicians (cardiologists and cardio-
vascular surgeons) and engineers. The medical community should understand 
the value of in vitro testing and the problems associated with such 
testing studies. On the other hand the engineer should understand the 
problems faced by the cardiovascular surgeon and cardiologist. The 
communication should take place in both directions. 
PROSTHETIC HEART VALVES: A STUDY OF IN VITRO PERFORMANCE 
LETTER REPORT (6/1/81 - 6/30/81)  
The FDA contract on the in vitro flow characteristics of 
prosthetic heart valves officially started on 6/1. Due to spring 
quarter examinations, graduation and quarter break, actual work on 
Phase I of the project did not start until 6/22. We have since then, 
run a complete and thorough computerized literature search on prosthetic 
heart-valve performance. The search which includes both medical and 
engineering literature dates back to about 1967. In addition, we have 
contacted the major valve manufacturers (Edwards, Shiley etc.) to provide 
any articles they may have. We are presently in the process of xeroxing 
important articles (identified from the computer search) both at Georgia 
Tech and the Emory University Medical school. Professor Yoganathan and 
Dr. Harrison met for two days (June 26 & 27) in Los Angeles. They 
discussed material that could be used for Phase I. 
The following prosthetic heart valves will be studied in Phase I: 
Starr-Edwards (ball valve), Bjork-Shiley, Kay-Shiley, Beall, Smeloff-Cutter, 
Braunwald-Cutter, Lille hei-Kaster, Hall-Kaster, Hancock, Carpentier-Edwards, 
Ionescu-Shiley, St. Jude, and Angell-Shiley. 
PROSTHETIC HEART VALVES: A STUDY OF IN VITRO PERFORMANCE 
LETTER REPORT (7/1/81-7/31/81)  
Work on phase I of the project started in earnst. Articles on 
the different valves mentioned in last months letter report are being 
read and analyzed. We have during the past month concentrated on the 
medical (surgical and clinical) literature. Articles that pertain to 
large groups of valve recepients are being favored. Books on heart 
valve prostheses are also being studied. The scientific documentation 
of the medical articles leaves much to be desired, and we are doing 
our very best to extract as much quantitative and relevent qualitative 
data as possible. Well documented in vivo hemodynamic data on normally 
functioning prosthetic valves has been collected and is being tabulated. 
The amount of such data available varies tremendously from one valve 
type to the next. There seems to be a fair amount of data on the St. 
Jude and Hall-Kaster valves due to FDA regulations. For some of the 
older valve types very little good data exists. Once again documentation 
is sketchy. 
One of the most obvious areas where there is a tremendous lack of 
information is on the pathology of recovered (surgery or autopsy) heart 
valves and their respective hearts. At the present time only Dr. W. C. 
Roberts (NIH) has well documented pathology studies in the open literature. 
One of our medical consultants (Dr. Earl C. Harrison) has studied a large 
number of recovered heart valves. He has an extensive photographic library 
of these recovered valves. He has, however, not published detailed pathologic 
studies on his valve collection, due to the lack of financial resources and 
time. It is apparent to us, that there is presently no incentive at major 
valve centers to conduct detailed pathologic studies on recovered prosthetic 
vlaves. Therefore it is our opinion that a national center or centers be 
established immediately to study recovered prosthetic heart valves and 
related cardiovascular devices. 
When we complete our study of the medical literature, we will then turn 
our attention to the engineering literature for in vitro data on the various 
prosthetic heart valves. 
PROSTHETIC HEART VALVES: A STUDY OF IN VITRO PERFORMANCE 
LETTER REPORT (9/1/81-10/31/81) 
During the month of September the draft report for Phase I was completed 
and mailed to the sponsor. We are presently awaiting the technical review of 
the draft report. 
Phase II of the project was started on 9/1/81. In the experimental 
program we are studying the following valves: (1) Starr-Edwards-1260, (2) 
Starr-Edwards 6120, (3) Bjork-Shiley (convexo-concave), (4) St. Jude, (5) Beall, 
(6) Smeloff-Sutter, (7) Ionescu-Shiley, (8) Carpentier-Edwards, (9) Hancock 
(standard) and (10) Hancock (modified orifice). It is proposed to add the Hall-
Kaster aortic and mitral valves to study later on depending on the availability 
of time. 
Steady flow pressure drop studies are currently in progress, while the flow 
visualization studies were completed as planned at the end of September. As 
reported in our letter of October 19, the only problems with valves purchased 
under the contract pertain to the Carpentier-Edwards and Hancock porcine valves. 
We are presently attempting to get more stenotic porcine valves from both 
manufacturers. 
We have postponed the start of the velocity measurement studies to November 1 
due to the problems and questions we raised in our letter of October 19, to Dr. 
Letzing. Pulsatile flow velocity and pressure drop measurements are scheduled to 
start November 1. 
PROSTHETIC HEART VALVES: A STUDY OF IN VITRO PERFORMANCE 
Period: 11/1/81 - 11/30/81 
During the month of November the steady flow pressure drop measure-
ments were completed. Pulsatile flow pressure drop and regurgitation 
studies are presently in progress and we hope to finish them before the 
Christmas vacation. Pulsatile flow visualization studies are also 
presently in progress. 
We have not started the velocity measurement work mainly due to 
equipment problems. We have just received (11/30) equipment to convert 
the LDA to a 3-beam system. The PDP 11/03 mini-computer, which is inter-
faced on-line to the LDA system, had hardware problems for about a week. 
We intend to start the LDA studies the week of 12/7/81. We are, however, 
still awaiting a reply to our letter of 10/19/81. 
A detailed progress report for the period 10/1/81 through 12/31/81 
will be provided next month. 
PROSTHETIC HEART VALVES: A STUDY OF IN VITRO  
PERFORMANCE  
Letter Report (1/1 - 1/31/82) 
During the past month progress on the project was very slow due to two 
major reasons. A major snow storm in Atlanta closed Georgia Tech for a 
week. In addition, we had major problems with the new laser - Doppler 
equipment. The equipment was shipped to the manufacturer for repair and 
was returned to us on January 29. During the coming week we will put the 
LDA system back together again. 
During January we finished the leaflet photography experiments. We 
have also been analyzing the steady and pulsatile flow pressure drop and 
regurgitation results collected last year. After a complete analysis of this 
data, any experiments that have to be repeated will be scheduled. The pulsa-
tile flow visualization films were also processed during the past month. 
Since no written changes have been made to the contract the velocity 
and shear stress measurements will proceed as according to the original 
contract and our original proposal. Unless the changes we have discussed with 
Dr. Letzing are made officially by February 28, 1982, it may not be possible 
to incorporate the modifications into the contract without cost overruns. 
Please note that we requested for a contract modification on October 19, 1981. 
Dr. Letzing has requested that we study two Hall-Kaster valves in this 
contract. Money to purchase these valves, however, is not available in the 
budget. We discussed the possibilities of using two Hall-Kaster valves provided 
a couple of years ago by Medtronic Blood Systems, Inc. to Dr. Yoganathan. 
Since these valves were provided to an independent investigator, it is our 
current feeling that there may be legal ramifications if these valves were used 
in the FDA study. We therefore suggest that money be provided to purchase the 
two Hall-Kaster prostheses ( $2500). 
PROSTHETIC HEART VALVES: A STUDY OF  
IN VITRO PERFORMANCE  
Letter Report (2/1-2/28/82) 
Over the past month the buffer unit on the LDA system malfunctioned once again. 
The unit was returned to the manufacturer for warranty repair. Therefore during 
the past month we have made some preliminary steady flow velocity measurements in 
the aortic flow section. Without the buffer unit shear stress measurements were 
not possible. 
We are still analyzing the pressure drop, regurgitation, flow visualization, 
and leaflet photography data we collected over the past 3 to 4 months. Any 
experiments that have to be redone due to the analysis of this data, will be 
conducted during March and the first two weeks of April. 
During the month of February we received written comments from Drs. W. Let-
zing and S. Hilbert of the Bureau of Medical Devices, FDA, on the draft Phase I 
report. Their comments and suggestions are presently being incorporated into the 
final Phase I report. This report is being put on the Georgia Tech Cyber computer 
system word processor. 
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PROSTHETIC HEART VALVES: A STUDY  
OF IN VITRO PERFORMANCE 
Letter Report (4/1 - 4/30/82) 
Over the past steady flow velocity measurements have been conducted 
in the aortic position. The following valves have been studied at a 
steady flow rate of 417 cm
3
/s: (i) St. Jude Medical bi-leaflet, (ii) 
Starr-Edwards 1260 ball, (iii) Ionescu-Shiley pericardial, (iv) Bjork-
Shiley tilting disc and (v) Hall-Kaster tilting disc. The results from 
these preliminary studies will be analyzed during the next month. If 
these results are satisfactory, pulsatile flow velocity measurements 
should start in June. 
The reason for starting with the steady flow studies was to under-
stand the proper operation of our new 3-beam (2-dimensional) LDA system. 
It would have been technically futile to try the system out for the first 
time on a pulsatile flow field. The consequences could have been disasterous. 
We have completed our analysis of the pressure drop, flow visualization 
and leaflet photography data. Approximately a half dozen experiments have 
to be repeated to complete the data collection for this phase of the 
experimental study. These experiments will be completed this month. 
The final version of the phase I report was completed and should have 
reached the FDA by now. It is our opinion that phase I was a great success. 
Letter Report (6/1 - 6/30/82)  
During the month of June we moved our experimental facilities 
to a larger laboratory area. The move was necessitated by the 
growth of our research group, its activities and associated research 
equipment. We also purchased a PDP 11/23 MINC mini-computer system 
(Digital Equipment Corp.) to be interfaced with the 3 beam (two 
dimensional) laser-Doppler anemometer system. We are currently 
working on modifying our old software for on-line data collection 
and analysis. We anticipate that the software modification should 
be completed by the end of July. 
During mid-June we started the pulsatile flow velocity measure-
ments in the aortic flow channel. We have so far conducted experi-
ments on the St. Jude bi-leaflet and Bjork-Shiley tilting disc 
valves. We hope to complete the experiments in the aortic flow 
channel by the end of August, if no equipment problems arise. 
Measurements are being made downstream of the valves at mid-acceler-
ation, peak systole and mid-deceleration. At each spatial location 
at a fixed instant in the cardiac cycle at least 1000 data points 
are being collected. The collected data is being checked for its 
accuracy and statistical validity. Due to vibrations of the pulse 
duplicator system we are currently having problems measuring the 
wall shear stress accurately. At present we are able to measure 
velocities within 0.2 mm from the flow channel wall. We are 
attempting some new experimental procedures which we hope would 
allow us to measure velocities closer to the wall. 
PROSTHETIC HEART VALVES: A STUDY OF  
IN VITRO PERFORMANCE 
Letter Report (7/1 - 7/31/82) 
Professor Yoganathan was away in Europe during the month of July at-
tending the 3rd International Conference on Mechanics in Medicine and Bi-
ology at Compeigne, France, and visiting Bio-Fluid Dynamic Laboratories 
in Western Europe. At the 3rd ICMNB he presented a paper on the work 
conducted under Phase I of this project. The paper was well received. During 
the trip, many questions were raised about the Bureau of Medical Devices' 
current testing guidelines and clinical trail procedures for new prosthetic 
heart valves. It appears that within the next year or two West Germany 
and Great Britain are going to have in-house in vitro testing procedures, that 
will probably be more extensive and sophisticated than the current draft BMD 
guidelines require. 
While Dr. Yoganathan was away in Western Europe the pulsatile flow 
velocity measurements in the aortic positions were continued by his graduate 
students. However, in mid-July problems developed with the Georgia Tech campus 
air compressor. The compressor leaked an unusually large amount of oil into 
the air supply system, and this caused the three-way quick acting solenoid 
valves on the pulse duplicator system to malfunction. We, therefore, have had 
to order new solenoid valves, which should arrive by mid-August. Pulsatile 
flow velocity measurements have been conducted on the: St. Jude bi-leaflet, 
Bjork-Shiley, Hall-Kaster and Ionescu-Shiley heart valves. If the new solenoid 
valves arrive as promised (by the vendor) by 8/15/82, we still hope to finish 
the experiments in the aortic flow channel by the end of the month (see Letter 
Report: 6/1 - 6/30/82). 
Prosthetic Heart Valves: A Study of  
In Vitro Performance 
Letter Report (9/1 - 10/5/82) 
During the past month we have been writing computer programs on the 
MINC 11/23 mini-computer system, to analyze the pulsatile flow velocity 
data collected in the aortic flow chamber. We hope to complete the 
analysis of this data sometime this month. It is planned to start the 
mitral chamber measurements by November 1. Due to the delays we have had 
and the large amounts of data collected, we have requested a three month 
no-cost extension to the project. This would terminate the project on 
2/28/83. We feel this extension is necessary for us to complete the project 
in a satisfactory scientific manner. 
We are still attempting to find a paint that will adhere on to the 
surface of the Starr-Edwards ball during pulsatile flow. I have discussed 
the problem with Dr. E. Mueller at the Center for Medical Device Analysis. 
He is also looking into the problem. The Ionescu-Shiley pericardial valve 
that was purchased for the project developed a cuspal tear(fatigue)during 
the aortic velocity measurements. This valve can no longer be used. The 
valve will be returned to Dr. Mueller. Therefore, it will not be possible 
to conduct further studies on the Ionescu valve. 
Prosthetic Heart Valves: A Study of  
In Vitro Performance 
Letter Report (10/1 - 10/31/82) 
During the month of October we continued to analyze the pulsatile flow 
velocity data obtained in the aortic flow chamber. Most of the data appears 
to be in good order. It is, however, apparent that some of the experiments 
may have to be repeated to check for scientific accuracy and consistency. 
The pulsatile flow velocity measurements in the mitral flow chamber will 
be started in November. The following valves are to be studied: (i) Beall 
disc valve, (ii) Hancock porcine valve, (iii) Bjork-Shiley (c-c) tilting disc 
valve, (iv) Hall-Kaster tilting disc valve and (v) St. Jude Medical bi-leaflet 
valve. Flow visualization studies conducted earlier in the project, indicate 
that the flow fields downstream of the Beall disc and Hancock porcine valves 
are relatively symmetric. Therefore with these two valve designs, it is proposed 
to make velocity measurements only across the central diameter of the prosthesis. 
With all five valves measurements will be made during: (i) mid acceleration, 
(ii) peak diastole and (iii) mid deceleration, downstream of the prostheses. 
In addition, measurements will be made upstream of the prostheses during valve 
closure. 
We have had no luck finding a paint that will adhere to the surface of 
the Starr-Edwards (1260) ball valve. We may have to resort to taping the 
surface of the ball. Doing so may effect the hydrodynamic performance of the 
ball. We will have to wait and see till we attempt the experiment. 
PROSTHETIC HEART VALVES: A STUDY OF  
IN VITRO PERFORMANCE 
Letter Report (12/1/82 - 1/7/83) 
During the month of December, pulsatile flow velocity measurements 
were conducted in the mitral flow chamber. Measurements were com-
pleted on the Beall, St. Jude, and Bjork-Shiley heart valve prostheses. 
Partial measurements have been made on the Hancock porcine valve. On 
12/24/82 one of the frequency counters of the LDA system malfunctioned. 
The unit was shipped to manufacturer for repair and is expected back in 
our laboratory on 1/10/83. The LDA experiments will continue as soon 
as the frequency counter arrives. 
On 1/7/83 Dr. Yoganathan met with Drs. W. Letzing and E. Mueller 
of the Bureau of Medical Devices, FDA to discuss the format for the 
final report on the project. Various options and formats were dis-
cussed, and will be outlined in a future memorandum to be written by 
Dr. Letzing. We anticipate starting work on a draft of the final 
report on 1/17/83. 
PROSTHETIC HEART VALVES: A STUDY OF  
IN VITRO PERFORMANCE 
Letter Report (1/8/83 - 2/3/83) 
As reported in our last months report, one of the frequency 
counters had to be shipped back to the manufacturer (DISA Electronics) 
for repair. The counter was not returned to us until 1/17/83. Since then 
we have completed pulsatile velocity measurements on the Hancock porcine 
and Hall-Kaster tilting disc valves in the mitral position. We received 
a new Ionescu-Shiley valve from Shiley Laboratories on 1/28/83. Same 
pulsatile velocity measurements have been done on this valve. 
We are just beginning to work on a draft of the final report. With 
that in mind three types of plots are enclosed. Figure 1 contains thvee 
velocity profiles and the corresponding three shear stress profiles in 
pulsatile flow. Figures 2 and 3 show the velocity and shear stress 
profiles separately. It is our opinion that Figure 1 is far too busy and 
that the pulsatile velocity and shear stress data should be presented in-
dependently as in Figures 2 and 3. It also appears that instead of using 
multiple colors, three symbols (in black ink) would be preferable. We 
would appreciate any comments from Dr. Letzing on this matter. 
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PROSTHETIC HEART VALVES: A STUDY OF IN VITRO PERFORMANCE (January 18, 1982) 
Progress Report: 10/1/81 - 12/31/81 
During this period all steady flow pressure drops and flow visualization 
studies were conducted. The studies were conducted in appropriate aortic 
and mitral flow chambers over a steady flow rate range of 10 to 30 1/min 
(167 to 500 cm3 /s). We are presently analyzing the results of these steady 
flow studies. The initial results indicate that the prosthetic valves 
studied can be listed in the following order of increasing stenoticity: 
St. Jude, Hall-Kaster, Bjork-Shiley (C-C), Ionescu-Shiley, Hancock (MO), 
Smeloff, Carpentier-Edwards, Starr-Edwards, Hancock (std) and Beall. These 
results clearly indicate that the new low profile mechanical valves create 
smaller pressure drops compared to the older mechanical valve designs 
(caged-ball, caged-disc), and the porcine tissue valves with "average" 
muscle-shelf leaflets. 
As an example of the results of the flow visualization studies are 
given below with appropriate photographs. 
Bjork Shiley (Convexo Concave): Aortic Position, Steady Flow Visualization  
The Bjork Shiley is a tilting disc valve. The circular occluder is 
free-floating and opens off-center. It is suspended between two eccentrically 
situated stelite struts. Since the disc does not pivot on the tube cross-
section diameter, two asymmetric orifices are formed in the open position. 
In the photographs the valve is oriented such that the disc is seen from 
the side. It is not visible since it is black. Flow is from left to right. 
The larger, or major, orifice is above the disc. The jet through this 
orifice is seen above the shadow formed by the disc and slants upwards from 
left to right. The minor orifice jet appears to come out of the shadow in 
-2- 
the 25 l/m photograph. It is less visible in the 15 1/m photograph but 
is there. 
15 l/m  
At the low flow rate problems with low particle concentration were 
encountered,but essential details are visible. The major orifice jet slants 
upwards from left to right and impinges on the tube wall about 20 mm downstream 
of the valve. Flow separation is visible above the major orifice jet adjacent 
to the sewing ring. This causes a region of stagnation next to the sewing 
ring. Flow separation is also visible below the major orifice jet and above 
the minor orifice jet. The region of stagnation between these separations 
is directly downstream of the occluder. The minor orifice jet appears much 
broader than the major orifice jet and the flow is slower (shorter streaks). 
Although not visible in the photograph, observation revealed flow separation 
below the minor orifice jet adjacent to the sewing ring. This caused a region 
of stagnation next to the sewing ring. Farther downstream of the valve flow 
is very rapid downstream of the major orifice along the wall and much slower 
throughout the rest of the tube. This causes turbulence to persist downstream 
of the valve. 
25 1/m  
At the high flow rate the same flow details are there with some slight 
differences. The regions of stagnation appear smaller and are better defined 
by flow separation. Also, a greater turbulence intensity is visible downstream 
of the valve. 
Consequences of observed flow patterns  
Flow separation and regions of stagnation can lead to thrombus formation 
in the body. Clots on the downstream face of the disc have been observed 
-3- 
clinically (11,41). The low flow through the minor orifice combined with 
flow separation and stagnation adjacent to the sewing ring could lead to 
thrombus formation and excess tissue growth in this region. Excess tissue 
growth on the sewing ring around the minor orifice, sometimes leading to 
value dysfunction, has been observed clinically (11,41). The stagnation and 
flow separation above the major orifice jet would be less likely to cause 
thrombosis or excess tissue growth due to rapid swirling caused by proximity 
to the jet. The high turbulence caused by the major orifice jet could cause 
some blood cell damage leading to hemolysis and the release of clotting 
factors. The major orifice jet impinges on the wall about 20 mm downstream 
of the valve. Some damage to the endothelial tissue could occur. However, 
compared to a ball or flat disc valve, the chance of tissue damage would be 
less. This is because the angle of incidence is less than that of a ball 
or flat disc valve at a similar flow rate. 
Smeloff Sutter: Mitral Position  
Steady Flow Visualization 
10 1/m  
Flow is from left to right. The streamlines upstream of the valve 
appear to be parallel. Thus this valve does not appear to disturb the flow 
upstream of itself. The ball presents a large obstruction to flow causing 
significant radial flow. An angled jet can be seen which impinges on the 
wall at a location approximately even with the top of the cage. This jet 
could cause endothelial damage. This has been clinically observed in the 
aortic position (439). The turbulence caused by this jet, as well as the 
flow separation, could cause hemolysis and release of clotting factors. 
This has been observed clinically in some cases. Flow separation is seen 
-4- 
to the left of the jet causing a stagnation region adjacent to the sewing 
ring. In the body excess tissue growth and thrombus formation could occur 
here leading to possible valve dysfunction. The bases of the struts are 
in this flow separation/stagnation region and thrombus or excess tissue growth 
could occur there also. The separation caused by the struts themselves could 
also lead to similar problems. This separation was not visible here due to 
the orientation of the sheet of light above the valve and its width being 
comparable to that of the strut. Excess tissue growth on the sewing ring 
(262, 278) and thrombus formation on the downstream struts where they join 
the metal orifice ring (185, 263, 267, 268, 283, 284, 372, 439) have been 
observed clinically. Thrombus formation at the junction of the upstream 
struts and the metal orifice ring has also been observed clinically. 
The jet separates from the ball about 1/2 way around it. This leaves 
a region of stagnation downstream of the ball. The ball is rapidly moving 
in the body so that thrombus formation on it is very unlikely. The ends of 
the struts extend into this stagnation zone. However they appear to be 
washed by the"swirling fluid"due to the proximity of the jet. The most 
stagnant zone appears to be directly downstream of the center of the ball. 
Since the struts do not extend into this region, thrombus formation would 
probably not occur. Indeed this has not been a problem clinically unlike the 
Starr Edwards valve whose struts meet at the cage apex. 
The flow field downstram of the valve is very turbulent. Rapid flow 
along the walls eventually dissapates into large swirls resulting in some 
reverse flow along the center of the tube. This reverse flow tends to wash 
part of the ball and the downstream ends of the struts. It could also lead 
to ball instability. However, this was not observed for the Smeloff Sutter in 
the mitral position. 
-5- 
25 l/m  
At the higher flow rate the jet is more nearly horizontal and separates 
from the ball approximately 3/4 of the way around. A triangular shaped stasis 
region is clearly seen. The strut ends extend into this region but are washed 
by swirling fluid at the edge of the stagnation zone. The stagnation region behind 
and beside the ball, adjacent to the sewing ring, is much larger. Thus the 
problems of thrombus formation and tissue overgrowth on the sewing ring and 
at the strut bases would be expected to be worse. 
The flow pattern downstream of the ball is somewhat reversed compared 
to the low flow rate. The jet no longer impinges on the wall but travels 
down the center of the tube. This dissapates into swirls resulting in some 
reverse flow along the walls. 
Hancock (Modified Orifice): Aortic Position (Symmetric Section)  
Steady Flow Visualization  
10 l/m  
This tissue valve has a centrally opening orifice which causes a central 
jet. This jet is well defined in the photograph. It extends at least 40 mm 
downstream of the valve sewing ring before dissipating. Flow separation occurs 
at the edge of the leaflets causing a region of stagnation adjacent to the 
sewing ring and the out flow faces of the leaflets. It extends about 20 mm 
downstream of the valve. This would be a very probable site for thrombus and 
excess tissue growth formation. Both of these have been observed clinically 
(112, 194, 320, 324, 331, 332, 339, 350, 355, 356, 360, 315, 325, 327, 333, 
341, 343, 381). It may also encourage calific deposits on the out flow faces 
of the leaflets. 
-6-- 
The turbulence caused by this central jet is still visible 150 mm 
downstream of the valve when compared to the parallel streaks upstream of 
the valve. This could lead to some hemolysis which in fact has been observed 
clinically in the mitral and tricuspid positions. 
25 1/m  
At a higher flow rate the well defined jet extends to about 60 mm 
downstream of the valve. The stagnation region on the wall adjacent to the 
sewing ring extends about 40 mm downstream of the valve. 
-7- 
In addition, most of the pulsatile flow pressure drop, regurgitation 
and flow visualization studies have been conducted in both aortic and mitral 
flow chambers. The data from these studies are at present being analyzed in 
detail. Results from the pulsatile flow studies will be discussed in our 
next 3 month progress report. 
We are presently conducting leaflet photography studies on the tissue 
bioprostheses. Thexe experiments should be completed by the end of January. 
We have received all the equipment from DISA Electronics to convert our LDA 
system to a 2-D velocity measurement system. This system will allow us to 
measure axial and radial velocities and turbulent shear stresses on-line. 
Unfortunately, some of the new equipment we received is not functioning 
properly. As indicated in our letter of December 8 , 1981 two pieces of 
equipment were returned to DISA. Further LDA equipment, problems developed 
immediately after the Christmas vacation. These problems got worse during the 
first week of January. Therefore, the pieces of equipment which were 
malfunctioning were shipped to DISA on January 12. All the equipment is under 
warranty, and it is our hope that it will be returned to us within the next 
ten days. As soon as the LDA 2-D system is fully operational, the detailed  
pulsatile flow velocity and shear stress measurements will begin, 
PROSTHETIC HEART VALVES: A STUDY OF IN VITRO 
PERFORMANCE 
Progress Report: 1/1/82 - 3/31/82 
Progress during this three month period was extremely slow. The 
primary reason was the equipment failure problems we encountered with 
the laser-Doppler anemometer system. Most of these problems appear to 
have been corrected. Steady flow velocity and shear stress measurements 
were begun with the 3-beam LDA system in mid-March. By the second week 
of February we received comments on the draft Phase I report from Doctors 
Letzing and Hilbert of the Bureau of Medical Devices. Their comments 
have been incorporated into the final version of the report. The report 
is presently being typed on a word processor and should be completed by 
mid-April. 
The steady pulsatile flow pressure drop, regurgitation, flow visuali-
zation and leaflet photography data were analyzed. Some of the pulsatile 
flow data is still being analyzed. Experiments that needed to be repeated 
were conducted during this period. One of the graduate students who worked 
on the project is planning to write his MS thesis this quarter. His thesis 
will contain most of the steady and pulsatile flow results (other than the 
pulsatile flow visualization, and all the velocity and shear stress measure-
ments). Attached are some preliminary results of the steady flow velocity 
measurements. 
It is our hope that during the next three months all the steady flow 
velocity measurements will be completed in the aortic flow section. We 
also plan to start the pulsatile flow velocity studies in the aortic po-
sition. 
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PROSTHETIC HEART VALVES: 	A STUDY OF IN VITRO 
PERFORMANCE 
Progress Report: 1/1/82 - 5/31/82  
Progress during the first three months (1/1 - 3/31/82) was extremely 
slow. The primary reason was the equipment failure problems we encountered 
with the laser-Doppler anemometer system (see attached letters). Most of 
these problems appear to have been corrected. Steady flow velocity and 
shear stress measurements were begun with the new 3-beam laser-Doppler ane-
mometer system in mid-March. By the second week of February we received 
comments on the draft Phase I report from Drs. Letzing and Hilbert of the 
Bureau of Medical Devices. Their comments have been incorporated into the 
final version of the report. The final Phase I report was completed, typed 
on a word processor and mailed to BMD by May 10, 1982. 
The following items have been completed in accordance with the contract 
and our research proposal. 
1. Phase I with final report submitted on or around May 10, 1982 
2. Steady flow pressure drop measurements on the Starr-Edwards (1260 
and 6120), Smeloff, Bjork-Shiley, Hall-Kaster, Beall, St. Jude, 
Hancock (std. and mo), Carpentier-Edwards and Ionescu-Shiley valves 
in both aortic and mitral chambers. Experiments were conducted at 
various steady flow rates in the range of 5 to 30 2/min. 
3 	Pulsatile flow pressure drop studies have also been conducted on the 
above valves in the aortic and mitral chambers, at a cardiac output 
range of 2-5 to 7 - 5 k/min. In these experiments the mean systolic or 
diastolic pressure drops, and Qrms flow rates were measured at four 
different cardiac outputs. The data was all collected from the 
Georgia Tech pulse duplicator system via the Apple II plus micro- 
-2- 
processor system. From these measurements the effective orifice 
areas and performance indicies of the different valve designs have 
been obtained. 
4. Pulsatile regurgitation studies in both aortic and mitral chambers 
have been completed on all the valves except the Smeloff. According 
to the manufacturer of the Smeloff valve, this valve design has to 
be tested at 37 ° C in order to measure its proper regurgitant charac-
teristics. We are presently unable to do this on our pulse dupli-
cator system. The pulse duplicator can only be operated at room 
temperature (% 22 °C). 
5 	Steady and pulsatile flow visualization studies have been conducted 
on all the above valves in both chambers at physiologic conditions. 
The photographs were taken in the immediate vicinity of the valve 
prostheses. We now have a library of negatives on the flow visuali-
zation characteristics of the different designs. From these photo-
graphs we have been able to make detailed qualitative as well as semi- 
quantitative observations. In doing these experiments we had to 
experiment with different types of particles, films (ASA, etc.), and 
camera settings. 
6. Leaflet photography studies have been conducted on the Hancock (Std. and 
mo), Carpentier-Edwards and Ionescu-Shiley tissue valves, at two 
cardiac outputs. We are still in the process of measuring the leaf-
let opening areas from the photographs (slides). 
7. Over the past two months steady flow velocity and shear stress measure-
ments have been conducted in the aortic position. The following valves 
have been studied at a steady flow rate of 417 cm 3/s: (i) St. Jude Medi-
cal bi-leaflet, (ii) Starr-Edwards 1260 ball, (iii) Ionescu-Shiley peri- 
cardia, (iv) Bjork-Shiley tilting disc and (v) Ha11-Kaster tilting 
disc, Velocity measurements (axial and radial) were made along the 
flow channel centerline at at least two downstream locations. For 
the asymmetric flow fields, measurements were made off-centerline 
as well. Across each diametric traverse, measurements were made 
at 10 - 15 points. At each point 1000 - 2000 data samples were 
collected. These sample sizes give statistically valid data. 
The results from these preliminary studies are still being ana- 
lyzed. If these results are satisfactory, pulsatile flow velocity 
measurements should start in June. The reason for starting with 
the steady flow studies was to understand the proper operation of 
our new 3-beam (2-dimensional) LDA system. It would have been 
technically futile to try the system out for the first time on a 
pulsatile flow field. The consequences could have been disasterous. 
The following work has yet to be completed: 
1. Pulsatile flow velocity and shear stress measurements in the aortic 
flow chamber for the Starr-Edwards, Bjork-Shiley, St. Jude, Hall-
Kaster, Porcine and Ionescu-Shiley valves. 
2. Pulsatile flow velocity measurements in the mitral chamber for 
the Beall, Bjork-Shiley, Hall-Kaster, St. Jude and Porcine (probably 
Hancock std.) valves. 
It is planned to start the pulsatile flow aortic studies in June. Barring 
any unforseen problems we hope to complete the entire study within the next 
six months. We have therefore, requested a 3-month no-cost extension to the 
project. The pulsatile velocity and shear stress measurements will be per-
formed under the appropriate physiologic conditions, as well as data collec-
tion procedures, such that the final data that will be presented to the FDA 
-.4- 
is statistically valid and is of good quality, If any technical problems 
arise during the next six months, we will inform Dr. Letzing of such problems 
in our monthly reports. 
PROSTHETIC HEART VALVES: AN IN VITRO STUDY 
Progress Report: 6/1/82 - 9/6/82  
During the month of June we moved our experimental facilities to a 
larger laboratory area. The move was necessitated by the growth of our 
research group, its activities and associated research equipment. We also 
purchased a PDP 11/23 MINC mini-computer system (Digital Equipment Corp.) to 
be interfaced with the 3 beam (two dimensional) laser-Doppler anemometer 
system. We had to modify our old software for on-line data collection. We 
are currently modifying the data analysis software so that it is compatible 
with the PDP 11/23 system. 
Professor Yoganathan was away in Europe during the month of July at-
tending the 3rd International Conference on Mechanics in Medicine and Biology 
at Compeigne, France, and visiting Bio-Fluid Dynamic Laboratories in Western 
Europe. At the 3rd ICMMB he presented a paper on the work conducted under 
Phase I of this project. The paper was well received. During the trip, many 
questions were raised about the Bureau of Medical Devices' current testing 
guidelines and clinical trail procedures for new prosthetic heart valves. It 
appears that within the next year or two West Germany and Great Britain are 
going to have in-house in vitro testing procedures, that will probably be more 
extensive and sophisticated than the current draft BMD guidelines require. 
Steady flow velocity and shear stress measurements were made in the 
symmetric aortic flow channel at a flow rate of 417 cm
3
/s (25 k/min). This 
steady flow rate corresponds to the peak systolic flow rate at a cardiac output 
of about 4 to 5 Z/min. All measurements were made within a downstream distance 
of 30 mm from the valve sewing ring. The closest possible downstream 
measurement location varied depending on the valve design. The valve designs 
studied were: Bjork-Shiley and Hall-Kaster tilting disc valves; St. Jude bi-
leaflet valve; Starr-Edwards (1260) ball valve; and Ionescu-Shiley pericardial 
tissue valve. Most of the measurements were made in the forward scatter mode. 
The back-scatter mode was, however, employed to obtain measurements in the 
annular flow region created by the ball and tissue valves. With the 3 beam 
LDA system both axial and radial velocities were measured simultaneously. 
Each full profile consisted of about 15 - 20 data points. For each data point 
at least 1024 samples were collected and analyzed, to calculate mean velocity, 
normal stress, shear stress and rms turbulence quantities. With the tilting 
disc valves velocity measurements were made in the major orifice, minor orifice 
and along the center line. With other valve designs, measurements were made 
along the center line and above the center line. No measurements were made 
below the center line since flow visualization studies indicated that the flow 
fields were relatively symmetric about the center line. 
Pulsatile flow velocity measurements were made in the immediate vicinity 
of the Bjork-Shiley, Hall-Kaster, St. Jude, Starr-Edwards (1260) and Ionescu-
Shiley heart valve prostheses. Experiments were conducted at a heart rate of 
70 beats/min, systolic time of about 300 ms, physiological pressures and cardiac 
outputs of about 5 to 6 hours k/min. Measurements were made at the same loca-
tions the steady flow studies were conducted. A 20 to 30 ms time step was 
used for data collection. Data was collected at three different time instances 
during systole, namely: (i) mid-acceleration, (ii) peak systole, and (iii) 
mid-deceleration. As in the steady flow experiments, a full profile consisted 
of about 15 - 20 data points. For each data point at least 1024 samples were 
collected. In addition to the downstream measurements, measurements were 
also made upstream of the valves to study the regurgitation patterns of the 
different valve designs. Measurements were taken at the time of highest closure 
backflow and at mid-diastole. In pulsatile flow wall shear stress measurements 
were also conducted. Since only the axial velocity component is needed to 
calculate the wall shear stress, a two beam LDA set up was employed to increase 
the accuracy of the measurements. The closest data points were between 0.03 
to 0.06 mm from the flow channel wall. 
When conducting measurements with the Starr-Edwards ball valve in the 
back-scatter mode, it was necessary to paint the poppet black to reduce the 
interference from the reflected light. However, none of the black points we 
tried remained attached to the poppet surface in pulsatile flow. The paint 
peeled-off within a couple of minutes. Therefore, we have not conducted any 
back-scatter measurements in pulsatile flow. We are, however, working on 
the problem. 
Work to be done: 
1. Analysis of the steady and pulsatile flow data obtained in the aortic 
flow channel. 
2. Back-scatter measurements with the Starr-Edwards (1260) and Ionescu-Shiley 
valves in the aortic position. 
3. Pulsatile flow velocity measurements in the mitral chamber for the Beall, 
Bjork-Shiley, Hall-Kaster, St. Jude and Porcine valves. 
4. Analysis of data from item #3. 
5. Write final report. 
PROSTHETIC HEART VALVES: An IN VITRO STUDY 
Progress Report: 9/7/82 - 12/1/82 
Pulsatile flow forward-scatter velocity measurements were carried out 
to completion with the following aortic valves in the symmetric aortic flow 
channel: (i) Starr-Edwards (1260), (ii) Bjork-Shiley (C-C), (iii) Hall-Kaster, 
(iv) St. Jude, and (v) Ionescu-Shiley. Steady flow velocity measurements 
on these valves in the aortic flow channel were conducted previously. 
The pulsatile flow velocity measurements conducted in the aortic flow 
chamber are shown in Table 1. In addition, the studies that need to be 
completed in the aortic flow chamber are also indicated. 
During the latter part of September and most of October, we were 
modifying the existing data analysis software and writing new data 
analysis software to be compatible with our new PDP 11/23 INCV 	system. 
The latter part of October was spent analyzing some of the data collected 
in the aortic flow channel. Balance of the aortic flow chamber data has 
yet to be analyzed. 
We started the pulsatile flow velocity measurements in the mitral 
chamber during the first week of November. The data we, however, col-
lected during the first week turned out to be useless due to poor 
signal-to-noise conditions. We also experienced problems with the pulse 
duplicator system in attempting to reproduce a satisfactory mitral flow 
curve. We therefore only started useful data collection in the mitral 
chamber on 11/15/82.
* 
In all pulsatile flow velocity experiments a 20 to 30 ms time step 
was used for data collection. Data was collected at three different 
times during systole/diastole (aortic/mitral): (i) mid-acceleration, 
*Note: Georgia Tech was physically closed from 11/25 to 11/29 for 
Thanksgiving. It was not possible to conduct experiments 
during'this period. 
(ii) peak systole/peak diastole (aortic/mitral), and (iii) mid-deceleration. 
A full profile consists of 15 - 20 data points. For each data point at 
least 1024 samples were collected. 
Work to be Completed: 
Tables 1 and 2 indicate clearly the experiments that need to be 
completed, together with the estimated time for completion (in actual 
working days). It should be noted that the time estimates do not take 
into account any time that may be lost due to any equipment failures. 
In addition, the laboratory facilities at Georgia Tech will be physically 
closed from 12/23/82 to 1/3/83 for the Christmas period. After comple-
tion of the pulsatile flow velocity experiments, it is estimated that 
the data analysis will take about 30 - 40 days. 
During this contract a vast amount of data has been generated. 
It is therefore estimated that the draft final report will take about 
45 days to write. It is currently planned to start writing this report 
on 1/17/83. However, before we can start writing the report we need 
definite concrete input from the Dr. W. Letzing (project technical 
monitor), on or before 1/14/83. Any delays in this technical consul-
tation will lead to delays in writing the final report. We need guidance 
from Dr. Letzing as to what should be in the final report, how it should 
be organized and structured, what material should be emphasized, etc. 
Most of the consultation could be conducted over the telephone and then 
finalized in writing. 







TABLE 1: PULSATILE FLOW VELOCITY MEASUREMENTS 
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* Due to the larger opening angle of the H-K valve, in order to get a full profile with the 3 beam LDA we would 
have to make measurements about 40 mm downstream of the valve. 
+ Back-scatter measurements,if possible, in annular flow region between poppet/leaflet and flow channel wall 
** Some of these are half profiles 
TABLE 2: PULSATILE FLOW VELOCITY MEASUREMENTS 
IN THE MITRAL FLOW CHAMBER 
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3 2 10.0 
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✓indicates experiments completed 
* If obstruction is not caused by the larger opening angle; otherwise 3 additional half profiles will be made 
** Some of these are half profiles 
+ Back-scatter measurements, if possible, in annular flow region between leaflet and flow channel wall 
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i. 
ABSTRACT 
In order to identify and define the fluid dynamic characteristics 
of primary importance in quantifying heart valve performance, GTRI has 
carried out a paper study of this subject under contract with the FDA. 
where possible these fluid dynamic characteristics have been related to 
valve hemodynamics and clinical complications such as hemolysis, 
thromembolism, thrombus formation, tissue overgrowth and other valve 
dysfunctions. 
This Phase I study is intended to provide a better understanding 
for the need to establish in vitro flow testing guidelines which 
encompass state-of-the-art instrumentation and methodology. The study 
indicates very clearly that there is more to the in vitro and in vivo  
fluid dynamic performance of a heart valve prosthesis other than 
pressure drop and regurgitation. The study, also indicates the need for 
good clinical follow up data on heart valve recipients, analysis of 
sub-lethal and/or lethal damage to blood components and endothelial 
tissue, and detailed pathologic studies on recovered (at surgery and/or 
autopsy) valve prostheses. 
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I. BACKGROUND AND INTRODUCTION  
The major objective of this report is to attempt to correlate the 
in vitro fluid dynamic performance of prosthetic heart valves with their 
in vivo clinical and pathological findings. 	The aim is to clearly 
document any relationship between in vitro fluid dynamic performance and 
potential clinical and/or pathological findings and complications. In 
order to prepare this report and extensive study of appropriate and 
useful scientific literature (medical, and bio-medical engineering) was 
conducted. 
Over 450 articles and books have been read and analyzed during a 
two month period (7/1/81-9/2/31). A majority of these articles and 
books have been published in the domestic literature during the past ten 
years. Important articles in the scientific literature were identified 
from a computerized literature search (MEDLAR) which was conducted at 
the start of the project. In addition, pertinent information was 
obtained from some of the valve manufacturers and by private 
communication with certain investigators. Articles were numerically 
cataloged as they were received and read. Therefore, the main text will 
not contain references in numerical order. In order to recatagorize the 
more than 450 articles would have taken too much valuable time. It 
should be noted that a draft report had to be completed in 3 months 
(7/1/81-9/30/81). Of these 3 months, 2 months were spent collecting and 
reading the articles. The third month was spent analyzing the material 
read, and writing the draft report. After consultations with BMD 
personnel on the draft report, a final report was prepared during March 
and April, 1932. 
failure due to material fatigue or chemical change, (g) damage to the 
endothelial tissue lining of the vessel wall adjacent to the valve and 
(h) leaks caused by failure of the valve to close properly. Problems 
(a), (b), (e) and (g) are directly related to the fluid dynamics 
associated with the various prosthetic heart valves, and need to be 
addressed in more detail by investigators studying bio-fluid mechanics. 
The other problems are indirectly related to the fluid mechanics. The 
problems relating valve failure due to material fatigue or chemical 
change also need to be studied especially as they relate to 
bioprostheses. 
Tissue bioprostheses gained wide spread use during the mid-1970's. 
It was even naively thought by some of the tissue valve manufacturers 
that the ideal heart valve prosthesis had been discovered. The major 
advantage of tissue bioprostheses compared to their mechanical 
counterparts is that they have a lower incidence of thromboembolic 
complications. Therefore, tissue valves for a large part can be used 
without anticoagulation therapy to eliminate or reduce thromboembolic 
complications. Unfortunately, the tissue bioprostheses clinically used 
at present also have major disadvantages such as: (a) relatively large 
pressure drops compared to some of the mechanical valves, especially in 
the smaller sizes, (b) jet-like flow through the valve leaflets, (c) 
material fatigue and/or wear of valve leaflets especially in children. 
Because of these and other drawbacks valve manufacturers are now 
developing new designs of mechanical valves such as the St. Jude, 
Hall-Kaster and Omni-Science prostheses, newer designs of bioprostheses 
and trileaflet valves made from polymeric materials. 
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directly related to the fluid dynamics associated with the various types 
of valve prostheses. Blackshear and his co-workers (430,431) suggest 
that the shear stresses required in the bulk of the flow to hemolyze red 
blood cells are about 40,000 dynes/cm
2
. Nevaril and his co-workers 
(432) contend, however, that this value could be as low as 1500 
2 
dynes/cm . In vitro experiments (433-435) have also recently shown that 
platelets could be damaged by shear stresses of the order of 100-500 
dynes/cm 2. A formed element such as a red blood cell which adheres to 
the vessel wall or to a foreign surface (such as the valve 
superstructure) may be damaged by shear stresses of the order of 10-10 2 
dynes/cm
2  ( 430,431,436). Lloyd, et al., (408) indicate that sublethal 
damage to red blood cells could occur at shear stresses on the order of 
2 
500 dynes/cm or less. A very recent study by McIntyre (441) indicates 
that the red blood cells of heart valve patients are more filterable in 
micropores than compared to normal subjects, due to sublethal damage to 
the red cells of valve recipients. Lethal damage to red blood cells 
causes hemolysis which in turn leads to anemia. Sublethal and/or lethal 
damage to red blood cells could also lead to platelet adhesion, 
aggregation and coagulation, resulting in thrombus formation. 
Mechanical damage to platelets (lethal and sublethal) will eventually 
lead to thromboembolic complications. 
Fry (437,438) has conducted two studies on the effects of wall 
shear on the endothelial lining of the aortic wall. He found that the 
endothelial cells on the vessel wall could be damaged at wall-shear 
stresses of about 400 dynes/cm and could be eroded off the vessel wall 
2 
at shear stresses of about 950 dynes/cm . He observed that when the 
7 
blood cells could adhere onto the vessel wall. If the adhered red blood 
cell is exposed is exposed to shears on the order of 10 to 100 dynes/cm
2 
it will probably be lethally damaged and hemolyzed. Red blood cells 
contain ADP and a clot-promoting factor known as erythrocin. These 
substances are released into the plasma as a result of rbc hemolysis 
initiating both platelet aggregation and coagulation, which in turn may 
lead to thrombus formation. 
The mechanical damage to the blood elements, as well as to the 
endothelial tissue of the adjacent vessel wall, may in addition trigger 
the complex biochemical reactions which could lead to the excess fibrous 
tissue overgrowth observed on some recovered heart valves. Therefore, 
large wall and bulk turbulent shear stresses could cause serious 
problems and complications in vivo. 
It is also well known that regions of flow stagnation, flow 
separation and excessively low shear in immediate vicinity of the valve 
superstructure have been related to thrombus formation and/or excess 
tissue overgrowth on the prosthesis. The flow velocity, shear stress 
and pressure fields in the immediate vicinity of a given heart valve 
prosthesis design are directly related to the fluid dynamic 
characteristics of the prosthesis. Therefore, detailed in vitro fluid 
dynamic studies should help predict potential problems and complications 
that arise in vivo with different designs of prosthetic heart valves. 
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clinical problems related to the prostheses. 	The results should 
therefore reflect the in vivo hemodynamic performance of normally 
functioning prostheses. 	All the information presented in these tables 
were obtained directly from their respective articles. 	Valve areas 
(VA), or otherwise known as the effective orifice areas, were calculated 
by the various investigators from the Gorlin (405) or modified Gorlin 
(406) formulae. We will not discuss the pit-falls of these formulae 
since they are used in all cardiac catheterization laboratories. The in 
vivo valve areas give a good qualitative and/or quantitative ranking for 
the in vivo pressure drop characteristics of the various valves. If 
different valve designs were studied by the same investigators and/or at 
the same medical center, these results will have more quantitative 
significance. Even though the absolute values of VA may vary from 
center to center for a given valve design, the ranking of different 
valve types according to in vivo valve areas should generally be 
consistent. The main reasons for the variations in the absolute values 
from center to center are: (I) Inaccurate in obtaining cardiac 
catheterization data (pressures and flows), (ii) obtaining a 
statistically large enough patient population and (iii) different 
formulae used to estimate VA. The in vivo tables do not contain 
regurgitation data because this parameter cannot be quantitatively 
measured during catheterization, or other in vivo procedures. 
In vitro pressure drop, flow rate, and regurgitation data were in 
most cases obtained directly from their respective articles. From these 
data the valve areas (VA) (ie: effective orifice area) were calculated 
from the following formula: 
11 
absolute values among the different investiOtors is because different 
types of pulse duplicators and flow chamber geometries have been used. 
It should, however, be noted that there is better quantitative agreement 
in the in vitro pressure drop and regurgitation data between different 
investigators, than with the in vivo hemodynamic data from different 
medical centers. 
Information obtained from the in vitro flow visualization, and 
velocity and shear stress measurement studies will be discussed in the 
text. 
All the hemolysis and thromboembolic complication tables were 
constructed from information extracted from their respective articles. 
As can be seen from these tables there is no consistent scientific 
manner in which data on hemolysis and TEC's are reported in the medical 
literature. Elevated LDH levels, and reduced and/or absent haptaglobin 
levels are good indicators of intravascular hemolysis. Reduced 
half-lifes of red cells and platelets are in our opinion one of the best 
ways of monitoring mechanical (shear) damage to blood elements. Such 
tests are infrequently done in a clinical environment. Early TEC's and 
deaths are defined as those occurring during the first 30 days after 
valve replacement surgery. TEC events are expressed where possible as 
patient ratios and/or as a rate (% per pt. yr.). 
Based on these tables and other pertinent information in the 
literature, we have been able to draw certain conclusions about the 
hemolytic and thromboembolic potential of the different valve designs. 
The locations of thrombus formation, excess tissue growth and related 
valve dysfunctions will be discussed in the text. 
Sizes and Dimensions 
Size Sewing Ring Orifice Primary Orifice 
Diameter(mm) Diameter(mm) Area(cm2 ) 
21A 21 13 1.41 
23A 23 15 1.67 
24A 24 15 1.79 
264 26 16 1.94 
27A 27 17 2.16 
294 29 18 2.57 
31A 31 19 2.89 
20M 20 13 1.27 
22M 22 14 1.54 
26M 26 17 2.14 
28M 28 18 2.49 
30M 30 19 2.86 
32M 32 20 3.24 
3411 34 22 3.66 
*Dow Corning Trademark 
**Cabot Corporation Trademark 
***DuPont Trademark 
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Sizes and Dimensions 
Size Sewing Ring Orifice Diameter Primary Orifice Area 
Diameter(mm) (mm) (cm2 ) 
19A 19+ 12+ 1.21 
21A 21+ 14- 1.43 
22A 22+ 15- 1.70 
24A 24+ 16- 1.89 
26A 26- 17- 2.16 
27A 27+ 17+ 2.36 
29A 29+ 18+ 2.66 
31A 31- 19+ 2.92 
23M 23- 15- 1.70 
26M 26- 17- 2.16 
28M 28+ 18- 2.50 
30M 30+ 19+ 2.92 
32M 32+ 21- 3.30 
(iii) (Models 2400 Aortic and 6400 Mitral)  
Models 2400 (aortic) and 6400 (mitral) Starr-Edwards composite 
track valve prostheses are closed single-cage hollow metallic ball valve 
prostheses. The cage struts, poppets, and metallic closure supports on 
the inner aspect of the base ring are made of Haynes Alloy No. 21* 
(Stellite Alloy No. 21) and are easily seen radiographically. The 
inner aspect of the cage struts has no cloth covering and hence no metal 
cloth contact. The rest of the cage struts are covered by 
tubular-knitted porous polypropylene cloth. The orifice cloth is made 
from siliconized multi-filament Dacron** thread which together with the 
exposed metallic supports produces a composite seating surface which the 
ball impacts at closure. The sewing ring is made of Teflon*** and 
polypropylene cloth over a silicone foam padding. The Model 2400 valve 
has 3-strut cage while the Model 6400 cage has 4 struts. 
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(b) In Vivo Results 
The clinical hemodynamic results for the various designs of the 
Starr-Edwards ball valves are given in Tables 1-8. For the aortic 
prostheses, valve areas (VA's) of 0.92 to 1.9 cm 2 were calculated for 
valve sizes of 21 to 29 mm. For the mitral prostheses in the size range 
of 26 to 34 mm, VA's were in the range of 1. 14 to 2.7 cm 2. These values 
are similar to those observed with other ball valve prostheses. 
As Tables 11 and 12 indicate there are numerous articles on the 
hemolysis and thromboembolic complications created by the different 
designs of Starr-Edwards ball valves. The results in Table 11 indicate 
without a doubt that the completely cloth covered strut models 2300, 
2310, 2320, 6300, 6310 and 6320 caused moderate and in many cases severe 
hemolysis (36,104,120,154,163,222). The models 2 1400 and 6 1400 tend to 
cause less hemolysis compared to the other cloth covered Starr-Edwards 
ball valves (56,97,10 14,295). The models 1200/1260 and 6120 non-cloth 
covered valves cause mild to moderate hemolysis. The thromboembolic 
complications (Table 12) seem to be greater with the non-cloth covered 
models (1200, 1260, 6000, 6120) compared to the cloth covered models 
(2300, 2310, 2320, 21400, 6300, 6310, 6320, 6400). This fact is 
substantiated in clinical studies conducted on both cloth and non-cloth 
covered models by the same group of researchers (60, 79, 195, 99, 1014, 
250, 424). According to Lefrak and Starr, the cloth covered valves have 
an embolus free rate of 95% at 3 years versus 81% for the non-cloth 
covered prostheses ( 1412 p. 67). The TEC rates for the Starr-Edwards 
ball valves seem to be in the range 3 to 6.5% per pt. yr. with 
anticoagulation therapy and as high as 10% per pt. yr. without 
TABLE 1 
IN VIVO PRESSURE DROPS: STARR-EDWARDS 1200/1260 AORTIC VALVES 
Rest Exercise 
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21 10 NA 18 




23 12 NA 25 NA 1.30 
( - 5-55) (0.8-1.8) 
37 
8 15.4 NA 3.3 1.52 
(9-28) (2.8-4.3) (1.20-1.64) 
27 
5 18 NA 3.5 1.51 
6 mo (11-28) (2.8-4.3) (1.20-1.64) 
15 NA 3.3 1.40 27 
27 mo (11-31) (2.4-3.7) (1.23-1.60) 
24 18 NA 1 1 NA 1.23 
26 
( 0-35) 
3 12.3 NA 2.9 1.45 37 
(7-17) (2.6-3.1) (1.38-1.52) 
3 12 NA 2.9 1.45 27 
(7-17) (2.6-3.1) (1.38-1.52) 
5 10 NA 2.9 1.60 27 
(7-14) (2.7-3.1) (1.31-1.70) 
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VA 2 2 	cm 
28 10 9.1 2.6 1.45 29 
(5.6-12.5) (1.9-2.4) (1.25-1.85) 
25 7.3 NA 1.65 26 
( - 1-16) ( - 1-2.8) 
9 8 NA 1.78 33 
( - 5-13) ( - 1.2-2.2) 
30 2 11.0 3.2 2.15 29 (10.7-11.3) (2.4-3.9) (2.11-2.19) 
15 7.1 NA 2.06 26 
( - 2-16) ( - 1.0-2.5) 
6 8.9 NA 1.85 33 
( - 5-17) ( - 1.5-2.3) 
& 30 2M=6 11.6+3.5** 3.16+.84** 1.65+.3** 24.5+7.1 ** 4.78+1.37 ** 1.78+0.4** 75 
3M*4 (8-17) (1.8-4.3) (1.2-2.1) (14-37) (3.0-7.0) (1.3-2.7) 
6300C 







( - 10-20) 
3.02 
( - 2-4.2) 
1.62 
( - 1-2.5) 
28 
30 5 5.7 2.73 2.11 
( - 4-8) ( - 2.5-3.0) ( - 1.5-2.5) 28 
* * + SD 
TABLE 8 
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30 11 4.2 2.7 2.2 31 
(1.3-6.3) (2.0-4.3) (1.5-3.1) 
32 4 8.5 2.8 1.7 31 
(3.7-14.4) 	 (2.2-3.3) 	(0.7-2.3) 
TABLE 9 


















19 1260 5.0 1.04 419 p. 	181 
21 1200 26.6 6.0 2.4(075 min-1 ) 	205, 232 
21 1260 5.0 1.23 419 p. 	181 
23 1200 12.4 6.0 2.4(@75 min
-1
) 	205, 232 
23 1260 5.0 1.46 419 p. 	181 
na 
24 1260 15.9 1,6.3 20 1.62 417 qD 
24 2400 14.8 1,6.3 20 1.68 417 
24 2320 15.9 1,5.3 20 1.62 417 
24 2300 51(peak) 5.4 NA 307 
25 1200 13.7 4.0 1.5(@75 min
-1 
 ) 	205, 	232 
25 1260 5-7.2 1.86 419 p 181 
27 1260 16.1 1,5.3 20 1.61 417 
*27 1260 1,13.3 20 1.77 309 
27 1260 4.0 6.3(050 min
-1
) 	237 
4.0(880 min-1 ) 	237 
4.6(0110 min -1 )237 
3.5(0140 min-I)237 
*steady flow rate 
31 
6120) prostheses. The fact that the cloth covered models can see more 
hemolysis compared to the non-cloth covered models is highlighted in 
studies where both types of valves were investigated (36, 56, 97, 104, 
120, 154, 163, 222, 295). 
Hamby, et al., (452) in an excellent clinical study, demonstrated 
the hydrodynamic instability of the Starr-Edwards aortic ball valves in 
41 patients. The study combined cineflouroscopy, phonocardiography and 
hemodynamic measurements. In 20 of the patients the poppet remained in 
a relatively fixed position (even though it rotated) at the apex of the 
cage during systolic ejection. In 11 patients the poppet bounced away 
from the apex of the cage during early ejection and promptly returned to 
the apex during the remainder of the ejection period. In 10 patients 
premature partial closure of the valve was observed during ejection. 
After striking the apex of the cage during early ejection the poppet 
descended almost half the distance toward the base of the valve and 
remained in a relatively fixed, partially closed position during the 
remainder of the ejection period. Instability of the poppets of the 
Starr-Edwards ball valves has also been observed in some of our patients 
at the USC-LA County Medical Center. 
(c) In Vitro Results 
The in vitro pressure drop studies indicate calculated VA's of 1.04 
to 2.12 cm 2 for aortic and mitral valves in the 19 to 32 mm size range 
(Tables 9 and 10). As stated by Lefrak and Starr (412 p. 67) there is 
no difference in the in vitro pressure drop and regurgitant 
characteristics of the non-cloth covered (1200/1260, 6120) and the cloth 
covered (2310/2320, 2400, 6310/20, 6400) prostheses. The in vitro  
STARR-EDWARDS BALL VALVE (continued) 
HEMOLYSIS 
Position 	Model # LDH Hgb Hapt 	Other Remarks 	 RefU 
A 2310-20 794 IU/L NA NA 100 pts 	 104 
(<270)* 
A 2400 485 IU/L 
(<270)* 
NA NA 23 pts; model 2400 causes 	104 
less hemolysis compared 
to models 2300-10-20 
A 1000 162+22 units 
(23-75)* 
NA NA most of 15 had mild 	36 
hemolysis 
A 1200 196+22 units NA NA 13/13 had mild hemolysis 	36 
(23-75)* 
A 1260 190+19 units NA NA 26/26 had mild hemolysis 	36 
(23-75)* 1/26 had anemia 
A 2300 574+87 units NA NA 28/46 had anemia 	 36 
(23-75)* 46/46 had mild hemolysis 
A 2310 344+43 units NA NA 10/27 had anemia 	 36 
(23-75)* 27/27 had mild hemolysis 
A 2320 325+37 units NA NA 9/29 had anemia 	 36 
(23-75)* 29/29 had mild hemolysis 
A 2320 NA NA NA 135 pts; 24/135 had hemo- 	96 
lytic anemia 
A cloth-covered NA NA NA 12/14 had renal hemosidero- 120 
sis 
A non-cloth-covered NA NA NA 24/35 had renal hemosidero- 120 
sis 
NA NA NA NA NA 7/8 had anemia 	 143 




HEMOLYSIS STARR-EDWARDS BALL VALVE (continued) 
Position Model U LDH Hgb Hapt Other Remarks Ref# 
A 2300 2422+1790 
IU/L 
NA NA 15/15 had moderate to 
severe hemolysis 
161 
A 2310 1280+776 
IU/L 
NA NA 15/17 had moderate to 
severe hemolysis 
161 
A,M 2310-10-20 NA NA NA 61/1187 had severe 
hemolysis; 
195 
6300-10-20 5 required valve 
replacement 
A 1000,1200 NA NA NA 19/302 had moderate 60 
1260,2300 hemolysis 
A 2300 NA NA NA severe hemolytic anemia 




A 2300 NA NA NA 15% of 28 had hemolytic 
anemia 
80 
A 2310 NA NA NA 6% of 38 had hemolytic 
anemia 
80 
A 1000 NA NA NA 7/90 had hemolytic anemia 95 
A 2310-20 794 IU/L 
(<270)* 
NA NA most of 123 had mild to 
moderate hemolysis 
97 




NA 10.6-16.8 mg% plasma Hgb 
0.8-15.0 mg% 
14 had mild to moderate 
hemolysis 
98 
A,M 1260,6120 NA NA NA 97 had mild hemolysis 154 
A,M 
+ SEM 
2300,6300 NA NA NA 69 patients studied; 
significantly more 





results also indicate low regurgitant volumes for the Starr-Edwards ball 
valves. 
There have been a number of flow visualization studies conducted on 
the Starr-Edwards ball valves in the aortic and mitral positions (169, 
175, 199, 205, 211, 236, 30 14, 305, 310, 363, 416). Wieting (416) 
observed the flow patterns downstream from a 27 mm model 1250 ball 
valve, under pulsatile flow conditions. During systole he observed a 
large turbulent wake distal to the ball. He also found that the ball 
bounced at the apex of the cage and this probably increased size of the 
turbulent wake. The large amplitude bounces increased the relative 
velocity between the surface of the ball and the fluid flowing past it. 
Yoganathan et al., (417, 427) and Figliola (411) have also observed the 
poppet instability phenomena with the model 1260 valve. 
	
As observed by Yoganathan, et al., in their 	studies, 	the 
instability of the poppet leads to larger pressure drops across the 
prosthesis. Dellsperger and Wieting (305) studied a model 6400 valve. 
In the mitral position they observed boundary layer separation resulting 
in a stagnation point at the apex and a toroidal vortex downstream from 
the valve during most of diastole. Smeloff, et al., (175) under 
pulsatile flow observed an area of stasis at the apex of the cage and a 
region of flow separation adjacent to the sewing ring. Wright and 
Temple studied flow patterns around a 24 mm aortic (model 2400) and a 32 
mm mitral (model 6400) valves under pulsatile flow conditions. In the 
aortic position they observed a small disturbance extending about half 
the ball diameter immediately downstream from the apex of the cage. 
This region of flow gradually extended throughout systole until after 
TABLE 12 
THROMBOEMBOLIC COMPLICATIONS : 	 STARR-EDWARDS BALL VALVE 
Position Modell Patient 
Ratio 
Rate 
% per pt-yr 
Deaths 
6300-10 6/67 NA NA 
A 2310 37 phtients 
studied 
7 
A 2310 9% NA NA 
A 2400 NA 
A 1200 9/95 NA NA 
A 1000 45/157 NA 9(late) 
A 2300 0/34 NA 0 
A,M NA NA NA NA 
A,M, 2300-10-20 11/267 NA 2 
T&double 6300-10-20 
A 1000,1200 11/29 NA 0 
1260,2300,2320 
M 6120 NA 6.1+1.1 NA 
M 6310-20 NA 3.0+.7 NA 
Anticoagulation 	Remarks 	 Ref 0 
Warfarin 	 48 
NA 	 poppets held at 	58 
apex of cage by 
thrombus & fibrin 
none 	 early 	 54 
none 	 thrombus on struts 
or ring 	 89 
all patients 	3-TEC's early 	60 
6-TEC's late 
all patients 	9-TEC's early 	60 
67% on anticoagulation 	 60 
NA 	 reduced platelet 	91 
adhesiveness 
coumadin 	 63 
most on warfarin 	platelet survival 	101 
time shortened to 
2.5 days (model 1000) 
3.0 days(model 1200-60, 
2300-20);Eromnormal of 
3.4 days 
all patients 	 99 
all patients 	 99 
+ SEM 
THROMBOEMBOLIC COMPLICATIONS ; STARR-EDWARDS BALL VALVE (continued) 
Position Model/ Patient 
Ratio 
Rate 
X per pt-yr 













164 patients studied 	104 
1 year post-op 
64 patients studied 	104 
8 years post-op 
M NA 13 patients 
studied 
none platelet survival time 106 
5.5 + 23 days, nor- 
mal 6.7 + .2 
A,M 2300,6300 23/153 NA 7 warfarin 107 
A,M NA allobserva-
tions on autopsy 
49/71 on warfarin 71/96 had thrombus on 	120 
mid-portion of struts 
5 at apex of cage 
A,M NA all observa-
tions at autopsy 
7/17 on warfarin 17/20 valves 	 121 
had thrombus 
A 2300 9/72 NA 1 none 67 
A 2300-10-20 14/147 NA 2 all patients 100 
A 2300-10-20 20/82 NA ' 	1 none 100 
A 2400-10 17/327 3.3 + .8 3 all 	patients 70 
M 6400-10 28/270 4.6 + 	.9 0 all 	patients 70 
A 2310 - - - coumadin fibrin deposits 	72 
on inside of each 
strut -1 patient 
A 2320 - - - coumadin severe cloth 	90 
wear led to TEC, 1 
pt. 
+ SEM 
THROMBOEMBOLIC COMPLICATIONS ; STARR - EDWARDS BALL VALVE (continued) 
Position Model# Patient Rate Deaths Anticoagulation 
Ratio % per pt-yr 
A 2310 1% NA NA coumadin 
A 2320 0% 0 0 coumadin 
M 6000 61% NA NA coumadin 
M 6120 20% NA NA coumadin 
M 6300 27% NA 0 coumadin 
M 6310 8% NA NA coumadin 
M 6320 0% 0 , 0 coumadin 
A,M 2300-10 
6300-10 
4% NA NA warfarin or 
coumadin 
M 6000 6/17 NA NA NA 
A 2310 2/62 NA 0 warfarin 
A,M 2300-10 6/223(early) 2(early) coumadin 
6300-10 6/118(late) 2(late) 
A 1000 12/90 NA NA all Patients 
M 6000 27/65 NA NA all patients 
A 1000,1200 40/162 NA 17 all patients 
1260 







+ SEM _ 
1200,1260 53/249 5.0 	 2 
5.5 (second embolous rate) 
all patients 










platelet survial 	242 
time shortened to 
2.7+.17 days 






5 valves replaced at 	445 




the base of the three struts and extended about 2 to 5 mm downstream 
from the valve along the walls of the flow chamber. At a flow rate of 
25 1/min the region of stasis was about 7 to 8 mm in size. Maximum wall 
shears measured were on the order of 1750 dynes/cm 2 , and poppet wall 
shears were on the order of 2500 to 2800 dynes/cm 2 . Turbulence 
intensity levels as high as 50% were measured in the wake region 
immediately downstream from the poppet, and in the annular region 
between the poppet surface. Maximum turbulent shear stresses on the 
order of 2000 to 5000 dynes/cm 2 (peak values) were measured in these 
regions. 
(d) Correlation 
The in vivo and in vitro pressure measurements indicate that like 
other ball valves, due to its centrally occluding _design, the 
Starr-Edwards ball valves are moderately stenotic in the medium to 
larger sizes. In the smaller sizes the valves are very stenotic. 
Patients with this prosthesis would not be able to lead very strenuous 
life styles. The prosthesis does have low regurgitant volumes, the 
lowest among mechanical prostheses in current clinical use. The in vivo 
and in vitro data seem to indicate that the instability of the silicone 
rubber poppet (1200/1260, 6120) could lead to larger pressure drops 
across the prosthesis. 
The large wall shear stresses created by the Starr-Edwards ball 
valves could cause lethal damage to the endothelial lining of the vessel 
wall adjacent to the valve, especially in the aortic position. The bulk 
turbulent shear stresses are large enough to cause sub-lethal and/or 
47 
mainly occurred on the inner aspects of the cage. The cloth covering 
along the inside of the orifice probably also causes flow separation, 
and if so could lead to excess tissue growth along the fabric in the 
orifice and cause the valve to become stenotic. 
4 9 
Sizes and Dimensions 




Orifice 	Primary Orifice 
Diameter (mm) 	Area( cm 2) 
19 19 19.6 12.3 1.19 
21 21 25.7 14.0 1.54 
23 23 27.6 15.1 1.83 
24 24 28.7 16.1 2.05 
26 26 30.7 17.1 2.31 
29 29 34.7 19.1 2.85 
31 31 38.3 21.0 3.45 
33 33 41.9 22.9 4.10 
34 34 44.2 24.1 4.56 
(b) In Vivo Results 
Very little good clinical hemodynamic data exists on the 
Smeloff-Cutter valve (Tables 13 and 14), inspite of the fact the 
prosthesis has been in clinical use for almost 15 years. The little 
hemolysis data that exists on Smeloff-Cutter valve patients (Table 17) 
does also indicate instances when hemolytic anemia has occurred. 
Sensitive quantitative blood studies such as LDH and haptaglobin levels 
are sadly lacking in Smeloff-Cutter valve recipients. Thromboembolic 
data (Table 18) show that this prosthesis has TEC rates in the 
approximate range of 1.5 to 6.5% per pt. yr. Patients with mitral 
prosthesis have the higher TEC rates. Thrombus formation on the valve 
superstructure has been observed on recovered Smeloff-Cutter aortic and 
mitral valves (185, 263, 267, 268, 283, 284, 372, 439). In most cases 
thrombus formation has been found at the junctions of the downstream 
struts and the metal orifice ring. Thrombus has also occasionally been 
found at the same junctions on the upstream side. Smeloff-Cutter aortic 
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NA 	4 	 4.13 	 2.85 	NA 	 4 	7.7 	 3.13 	NA 	262 
TABLE 14 
IN VIVO PRESSURE DROPS: SMELOFF-CUTTER MITRAL VALVE 
TABLE 
IN VITRO PRESSURE DROPS: 
15 
SMELOFF-CUTTER AORTIC VALVE 
Tissue Annulus Model Ap CO 9 r M S 
VA RV Ref 	i/ 
Diameter 
mm 
mmHg amin I/min cm
2 
 cm /stroke 
24 12.7 n..5.3 20 1.81 417 
24 37(peak) 5.6 NA 307 
24 9.3 6.0 6.4 	(@75 min
-1
) 205,232 
26 11.8 '.5.3 20 1.88 417 
*26 13.3 20 1.77 309 
*26 n., 	9.5 20 2.09 177 
26 12.8(peak) 3.24 21.4 9.3 (@72 min
-1
) 306 
8.2 (@78 min-1 ) 306 
11.0 (@55 min -1 ) 306 
*steady flow data 
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his studies (304, 410) observed that the separated region behind the 
ball was relatively small. He also observed a very short-lived small 
vortex forming in the wake region during late systole. In addition, in 
his studies as the valve opened during systole the ball bounced several 
times against the downstream cage and finally settled on the fifth cage 
contact. 
Yoganathan, et al., (353, 354, 417, 425) have made velocity and 
shear stress measurements immediately downstream from a size 26 
Smeloff-Cutter aortic valve at steady flow rates of 10 and 25 1/min. At 
the high flow rate they measured wall shear stresses as high as 1670 
dynes/cm2 and estimated maximum turbulent shear stresses to be on the 
order of 1000 to 4000 dynes/cm2 . The flow field was found to be most 
turbulent in the annular region between the occluder and aortic walls 
and the wake region immediately downstream from the occluder and cage. 
Figliola, et al., (351, 411) have also made similar observations with a 
Starr-Edwards 1260 ball valve. Yoganathan, et al., also observed that 
there was no region of stagnation near the apex of the downstream cage. 
Instead, negative velocities on the order of -10 to -20 cm/s were 
observed creating a washing effect at the apex of the cage. Regions of 
flow separation were observed adjacent to the sewing ring and near the 
base of the aortic side from the cage struts, along the downstream 
struts and immediately downstream of the ball (i.e.: wake region), 
similar to those observed by Figliola,et al., with the Starr-Edwards 
ball valve (351, 411). Hwang, et al., (419 p. 91) have made 
preliminary velocity and shear stress measurements downstream from a 
size 26 aortic valve under pulsatile flow conditions. The measurements 
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were made about 40 mm downstream from the valve sewing ring at a cardiac 
output of 4.2 1/min. They measured a maximum turbulent shear stress of 
about 320 dynes/cm 2 . This value seems low and is probably due to the 
fact that the measurements were made only 40 mm downstream from the 
valve and not any closer. Since the laser-Doppler anemometer was not 
able to measure flow directionality they were not able to observe any 
regions of flow separation. 
(d) Correlation 
The in vivo and in vitro pressure measurements indicate that the 
Smeloff valve is stenotic because of its centrally occluding design 
characteristics. The wall shear stresses, like for other peripheral 
flow prostheses, are elevated and could cause damage to the endothelial 
lining of the vessel walls adjacent to the valve. The problem would be 
most severe in the aortic position because of the proximity of vessel 
wall surfaces to the prosthesis (i.e., the region between the wall 
surfaces and poppet surfaces are narrow, compared to that present in the 
ventricle for the mitral valve). Roberts, et al., in their pathologic 
studies of ball and disc type valves observed damage to the endothelial 
lining of the vessel wall (mostly aortic) adjacent to the prosthesis 
(116, 117, 119-112). 	The damage causes intimal proliferation of 
fibrotic tissue on the vessel wall. 	On rare occasions this intimal 
proliferation in the aortic position may extend into one or both 
coronary arteries and cause sudden death. Roberts states (116) that it 
is likely that this intimal proliferation will progressively increase 
with time. 
THROMBOEMBOLIC COMPLICATIONS : 	 SMELOFF-CUTTER BALL VALVE (continued) 
Position 	Modell/ 	Patient 	Rate 	 Deaths 	Anticoagulation 	Remarks 	 Ref # 
Ratio % per pt-yr 
A 	 4/358 	 2.9 	 NA 	aspirin and 	 285 
dipyridamol 
A 	 4/358 	 5.4 	 NA 	 none 	 285 
M 	 1.2% 	 NA 	 0 	 all patients 	 54 
M 	 3/27 	 NA 	 3 	 NA 	 54 
A 	 3/33 	 NA 	 0 	 warfarin 	 thrombus formation on 284 
V21 recovered valves 
M 	 13/56 	 NA 	 2 	 NA 	 2 thrombosed valves 	263 
caused death 
4. 
BRAUNWALD-CUTTER BALL VALVE 
(a) Valve Description 
The Braunwald-Cutter prosthesis is an open cage ball valve. 	The 
entire valve housing is machined from a single piece of titanium, and is 
completely covered with cloth. The orifice cloth is made of 
polypropylene while the struts are covered with knitted Dacron tubing. 
The poppet is made of silicone rubber and is housed within a three strut 
cage. The valve has been used in both the aortic and mitral positions 
since 1968. The clinical use of the valve was discontinued around 1975. 
Sizes and Dimensions 
Size Sewing Ring Orifice Diameter Primary Orifice 
Diameter(mm) (mm) Area(cm2 ) 
A20 20 12.4 1.21 
422 22 14.4 1.62 
A23 23 15.2 1.82 
A24 24 16.0 2.01 
A25 24 17.7 2.45 
A27 25 18.6 2.72 
A29 29 20.2 3.21 
M26 26 15.2 1.81 
M28 28 16.8 2.22 
M30 30 18.4 2.66 
M32 32 20.0 3.14 
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CM 	 cm /stroke 
Tissue Annulus 	 Model 
Diameter 	 0 
mm 
*23 '1. 37.0 	 20 	 ti 1.06 	 84 
TABLE 21 
IN VITRO PRESSURE DROPS: BRAUNWALD-CUTTER AORTIC VALVE 







Model # LDH 	Hgb 	Hapt 	Other 	Remarks 	 Ref# 















3/3 had severe hemolysis 	76 
due to cloth wear 
M 	 elevated levels NA 	normal 	 10 pts. studied, all had 	18 
mild hemolysis 
(c)In Vitro Results 
As can be seen from Tables 21 & 22 in vitro fluid dynamic data on 
the Braunwald-Cutter valve in the open literature is non-existent. No 
flow visualization studies on this valve exist. It is our opinion that 
velocity profiles would be similar to those obtained with the 
Starr-Edwards and Smeloff-Cutter valves. 
(d)Correlation 
The Braunwald-Cutter prosthesis like other ball valves is stenotic. 
Patients with this valve would have to lead a rather low-profile life 
style. If the assumptions made in the in vitro section are correct, the 
wall shear stresses created by this valve could also lead to endothelial 
damage of the vessel walls adjacent to the prosthesis. The turbulent 
shear stresses could cause sub-lethal and/or lethal damage to red cells 
and platelets. 	Such shear damage could lead to hemolytic and 
thromboembolic problems. 	Red cells and platelets would also have 
reduced half-lifes. Thrombus formation and tissue overgrowth could 
occur at the base of the struts due to the flow separation at those 
locations. Therefore the thromboembolic and mild hemolytic problems 




IN VIVO PRESSURE DROPS: KAY-SHTLEY MITRAL VALVE 
Rest 
Tissue 	IN 	MG 	PG 	CI 	VA 1 
2 	
IN 	MG 	PG 	CI  VA., 
-1 2 	cm - 1 Annulus ref# 





















28 1 13 1.97 
1 9 4.7(CO) 
30 5 9.6 2.88 
(5-15) (1.8-4.7) 
31 6 9.6 2.78 
(0-22) (2.05-3.22) 
33 1 30 1.37 
MG Series 
27 1 14 4.0(CO) 
31 7 6.6 3.9(C0) 
f4-)0) (2.7-5.61 
33 5 4.6 4.4(C0) 
(3-7) (3.8-5.4) 
(b) In Vivo Results 
The Kay-Shiley mitral valve had calculated VA's of 0.9 to 2.1 cm
2 
in the 28 to 33 mm size range (Table 25). These results indicate this 
prosthesis was more stenotic than the caged ball type valves. As Table 
27 indicates there are very few articles on hemolysis with the 
Kay-Shiley valve. The valve did not seem to cause clinically 
significant hemolysis, but probably caused mild hemolysis. One of the 
major problems with this prosthesis was, however, thromboembolic 
complications, as clearly shown by the data in Table 28. TEC rates as 
high as 34.4% per pt. yr. have been observed with this prosthesis. 
Thrombus formation on the valve superstructure causing dysfunction of 
the Kay-Shiley valve is well documented in the literature (30, 116, 119, 
120, 166, 167, 215, 224, 226, 227, 263, 370, 372, 419, p. 395). 
Thrombi were mainly located at the junction of the cage struts with the 
metal orifice ring, up the vertical struts for variable distances, and 
occasionally completely covering the entire metal superstructure. Clots 
have also been observed on the disc and on the sewing ring. The 
prosthesis has occasionally been completely occluded by thrombotic 
material. 
Excess tissue growth on the sewing ring has also been a problem 
with this prosthesis (103, 164, 224, 225, 372, 414 p. 598, 419 p. 
385). In some cases the movement of the disc was severely restricted 
because of tissue overgrowth between the disc and sewing ring. In other 
cases part of the disc has been trapped by tissue overgrowth and 
thrombus formation. Such entrapment has transformed the disc into a 
73 
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hinged mechanism, thereby reducing the flow orifice, as well as leading 
to accelerated edge wear of the disc by the metal struts (412 p. 177). 
Excess tissue growth along the sewing ring have on occasions impaired 
the rotation of the disc. This impairment has led to grooving of the 
downstream face of the disc from mechanical contact with the horizontal 
struts (164, 372, 439). 
(c) In Vitro Results 
Very few in vitro studies exist on the Kay-Shiley valve. Weiting 
has observed the flow patterns around a 28mm Kay-Shiley valve in an 
aortic chamber (416). He observed a symmetrical toroidal vortex and a 
wake downstream from the disc caused by boundary layer separation during 
systole. He also observed an area of stasis at the center of the distal 
surface of the disc. The flow was jet like in the regions between the 
disc and the flow channel walls. Similar flow visualization studies and 
observations have been made by Duff (410). Figliola (351, 411) has made 
velocity and shear stress measurements downstream from a 27 mm 
Kay-Shiley valve (T series) in an aortic chamber under steady flow 
conditions. He observed a jet type flow between the poppet and flow 
chamber wall. He also observed flow separation at the sewing ring, and 
at the junction of the vertical struts and the orifice ring. A large 
wake with recirculating flow was monitored downstream from the face of 
the disc. At a flow rate of 25 1/min he measured a maximum wall shear 
stress of 2548 dynes/cm2 , turbulence intensities of 48% and Reynolds 
shear stresses of BOO dynes/cm2 . He also was able to measure shear 
stress of about 775 dynes/cm2 at the occluder wall surface. The 
THROMBOEMBOLIC COMPLICATIONS ; KAY-SHILEY DISC VALVE (continued) 
Position Modell Patient 
Ratio 
Rate 
% per pt. 
yr. 
Deaths Anticoagulation 
M T 2/23 NA NA all patients 
M MC 0/14 0 all patients 
M DMG 0/4 0 all patients 
A K&T 3/60 NA 1 anticoagulation 
discontinued in 
3 pts. 
M K&T 33/69 29.6 15 warfarin 
M NA 3patients none 
* normal values 
+ SEM 




death due to 	 227 
thrombosed valve 
370 
3 patients-platelet 	106 
survival time shortened 
to 5.5+ .23 days (6.7+.2)* 
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junctions of the vertical struts and orifice ring and near the sewing 
ring could lead to thrombus formation and tissue overgrowth at these 
locations. As stated previously clinical pathalogic findings indicate 
that these regions are the most prone to thrombus formation and tissue 
overgrowth with this valve. In addition, Roberts (116, 117) states that 
intimal proliferation of the vessel wall adjacent to valve (mainly in 
the aortic position) is probably most severe with the disc type valves. 






























31.7 1 NA NA 1.6 40 
Medium 8 7.9 NA 1.4 38 
(model (0-16) (1.1-1.6) 
104&105) 40 
6 NA NA 1.5 
Large 6 6.4 NA 2.3 38 
(model (3.5-10) (1.3-3.3) 
#104) 10 NA NA 1.7 40 
large=? 23 7.5+1.6* 3.39+0.4* NA 20 12.5+2.3 * 4.7+0.2 * NA 39 
Med. =14 (0-16) (1.6-6.2) (2-25) (2.3-9.0) 
Sm. 	=2 
Teflon models 
Small 7 15.2 3.28 1.43 5 24.9 3.63 NA 148 
(4.9-23.3) (1.70-3.92) (0.79-1.7) (20.0-28.4) (2.03-4.02) 
Medium 13 10.4 2.33 1.56 10 25.3 3.85 NA 148 
(4.2-14.9) (1.87-3.12) (0.62-2.58) (21.4-39.7) (2.81-4.97) 
Large 4 9.5 2.74 1.58 4 18.6 3.31 NA 148 
(8.0-12.8) 	(2.15-3.06) 	(1.50-1.73) 	(13.0-25.4) 	 (2.39-4.32) 
* +SEM 
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(b) In vivo Results 
The clinical pressure drop results obtained with the Beall valve 
indicate that it is even more stenotic than the Kay-Shiley disc valve 
(Table 29). Calculated VA's varied between 1.4 and 2.3 cm 2 for valve 
sizes in the 31 to 41 mm range. As shown by the data in Table 31 one of 
the major clinical problems with the Beall disc valve was the amount of 
hemolysis it caused. It has been suggested that the Dacron velour cloth 
covering used was the reason for the excessive hemolysis observed with 
this valve (412 p. 180). It has also been suggested that disc wear of 
the Teflon disc models exacerbated the native hemolysis of this 
prosthesis (1142). Nearly all patients who had this valve suffered at 
least mild intravascular hemolysis. A comparison of the "patient ratio" 
columns in Tables 28 and 32 tends to indicate that with anticoagulation 
therapy, thromboembolic complications with the Beall valve were not as 
severe as those observed with the Kay-Shiley valve. But as stated by 
Lefrak and Starr (412 p. 181) only a few publications have appeared in 
which time-related analysis has been utilized to analyze the rate of 
postoperative thromboemboli. Thrombus formation causing valve 
dysfunction has also been documented (38, 40, 142, 146, 190, 215). As 
stated by Roberts, et al., (117) disc type prosthses will develop 
thrombotic material at the junctions of the vertical struts and the 
orifice ring, along the vertical struts and across the face of the disc. 
Usually the amount of thrombus on the struts or primary orifice is not 
sufficient to interfere with the proper movement of the disc, and 
clinical evidence of systemic embolic incidents are infrequent when the 
prosthetic thrombi are small. Large thrombi may, however, obstruct flow 
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through the prosthesis and may immobilize the disc. They also state 
that prostheses of the disc type may be tilted in the cage by thrombus 
on one side, or thrombus may fill the entire space between the disc and 
the ring, causing complete immobility of the poppet (117). As observed 
with the Kay-Shiley valve the thrombus formation may cause improper 
motion of the disc (proper motion requiring movement up and down the 
cage, and rotation), thereby leading to grooving and notching of the 
disc (149, 150, 418 p. 463). 
(c)In Vitro Results 
In vitro fluid dynamic studies on the Beall disc valve are 
virtually non-existent in the open literature. It is doubtful if any 
such tests were even performed by the valve manufacturer when the valves 
were released in the mid to late 1960's. It is, however, our opinion 
that the velocity and shear fields downstream from this valve are 
similar to those observed with the Kay-Shiley and Starr-Edwards disc 
valves. 
(d)Correlation  
The Beall disc valve is a very stenotic valve design. 	If the 
assumptions about its in vitro fluid dynamic characteristics are 
correct, the wall and turbulent shear stress created by this valve could 
easily damage the endothelial lining of the vessel walls, and cause 
sub-lethal and/or lethal damage to blood elements, respectively. In 
addition, if the red cells were to attach themselves to the Dacron 
velour cloth covering, the shear stresses adjacent to the valve 
87 
superstructure would be more than sufficient to cause lethal red cell 
damage (hemolysis) as observed clinically with this prosthesis and the 
cloth covered Starr-Edwards ball valves. The region of flow stasis 
adjacent to the downstream face of the disc and the regions of flow 
separation at the junctions of the vertical struts and the orifice ring 
could lead to a buildup of thrombotic material at those locations as has 
been observed on some recovered Beall valves. The early model Beall 
valve was briefly utilized in the aortic position but its use in this 
location was abandoned because of obstructive, thrombogenic and wear 
characteristics (116, 117). Furthermore, Roberts in his pathologic 
studies observed that disc valves in the aortic position cause intimal 
proliferation of the aortic root, as a result of excessive wall shear 
stresses (116, 117). 
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modified valve was designed according to Dr. 	Bjork to improve the 
conventional Bjork-Shiley valve in three respects: (1) provide increased 
strength of the valve by making the inlet strut an integral part of the 
orifice ring and doubling its cross-sectional area (2) improve the 
hydrodynamics (3) reduction in the area of low flow and stagnation 
behind the disc. The design change includes the convexo-concave 
configuration of the disc and a pivot point which has been moved several 
millimeters downstream so that the disc in the open position is moved 
further out of the orifice ring. 
Valves manufactured after September 1975 have a radio-opaque 
tantalum loop incorporated in the pyrolytic carbon disc to allow 
evaluation of the opening angle of the disc. 
Sizes and Dimensions  




Primary Orifice Area 
(cm2 ) 
17 17 12 1.0 
19 19 14 1.5 
21 21 16 2.0 
23 23 18 2.5 
25 25 20 3.2 
27 27 22 3.8 
29 29 24 4.5 







19.4+4.1 ** 	1.67+.27 ** 













16.4+5.0 ** 1.67+.22 	7 	18.6+6.3 ** 








IN VIVO PRESSURE DROPS: 
TABLE 34 



























(b) In Vivo Results 
Clinical hemodynamic results indicate that the Bjork-Shiley valve 
has improved pressure drop characteristics compared to the centrally 
occluding (ball and disc) and porcine valve prostheses. Calculated 
valve areas varied from 1.06 to 2.56 cm 2 for aortic valve sizes of 19 to 
31 mm, and 1.8 to 2.6 cm 2 for mitral valve sizes of 27 and 29 mm (Tables 
33-35). The limited hemodynamic data tend to indicate no significant 
differences in the pressure drop characteristics of the spherical and 
convexo-concave disc aortic valves. Due to its world wide popularity 
there is a large amount of literature in the medical field on this 
prosthesis. 	Hemolysis data presented in Table 38 indicate that the 
Bjork-Shiley prosthesis can cause mild to moderate hemolysis. 	Patients 
with this prosthesis, however, rarely develop anemia because the body 
usually compensates adequately for the hemolysis caused by the valve. 
As shown in Table 39 the prosthesis has a TEC rate of about 4 to 6% per 
pt. yr. The major problem with the Bjork-Shiley valve is its potential 
to thrombose, sometimes catastrophically, especially in patients not on 
anticoagulation therapy (11, 13, 22, 23, 41, 45, 46, 47, 52, 53, 110, 
118, 44, 193, 197, 215, 277, 371, 392, 401, 419 p. 385, 446, 448). In 
addition to thrombus formation, excess tissue overgrowth has also been 
observed on recovered Bjork-Shiley valves. Please note that the above 
references all pertain to the standard (ie: spherical disc) Bjork-Shiley 
model (except ref 11, 41). There have been no long term studies on the 
convexo-concave model, and thrombus formation on this model has so far 
only been reported in two articles (11, 41). Thrombus formation mainly 
occurs on the outflow face of the disc especially in the well, and along 
IN VITRO PRESSURE DROPS: 8JORK-SHILEY AORTIC VALVE (CONTINUED) 
Tissue Annulus 
Diameter 















*27 C.C. 6.4 20 2.55 203 
27 std. 11.9(peak) 3.14 22.8(peak) N/A 15.1 	(@72 min
-1 
 ) 	306 
10.9 (@78 min-1 ) 	306 
20.8 (@55 min-1 ) 	306 
*27 std. '6.2 20 2.59 177 
27 std. 4.0 15.3 (@50 min 1 ) 	237 
4.0 10.6 (@80 min -1 ) 	237 
4.0 8.7 (@110 min -1 ) 	237 
4.0 7.4 (@140 min-1) 	237 
27 C.C. 4.0 13.0 (@50 min-1 ) 	237 up 
4.0 10.5 (@80 min-1 ) 	237 In 
4.0 7.8 (@110 min- I) 237 
4.0 6.0 (@140 min-1 ) 	237 
*steady flow data 
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the struts in the minor outflow region. However, thrombus formation on 
both the inflow and outflow faces of the disc has been observed in some 
recovered valves. Excess tissue overgrowth is observed mainly along the 
sewing ring of the minor outflow region. The amounts of thrombus 
formation and/or tissue overgrowth observed on recovered Bjork-Shiley 
aortic and mitral valves has varied from total valve occlusion to a thin 
layer. In some instances the combination of thrombus formation and 
tissue overgrowth has grown in such a manner to impede the complete 
opening of the tilting disc. In other instances, the disc has been 
found to be held immobilized in an open position by the vegetation. 
Therefore, it is of utmost importance that the physician be able to 
monitor the motion of the disc using cinefluoroscopy. 
(c) In Vitro Results 
The in vitro pressure drop results indicate (Tables 36 & 37) that 
the Bjork-Shiley valves have calculated VA's of 1.37 to 3.40 cm 2 for 
aortic and mitral valves in the 21 to 31 mm size range. There does not 
seem to be any significant difference in the pressure drop and 
regurgitation characteristics between the spherical and convexo-concave 
disc valves. Regurgitation data tend to indicate that at low heart 
rates and low cardiac outputs the Bjork-Shiley valve does have a 
significant regurgitant volume. 
There have been many flow visualization studies conducted on the 
Bjork-Shiley valve in both the aortic and mitral positions (7, 49, 52, 
141, 179 190, 199, 205, 211, 227, 232, 236, 305). Wright has studied 
the valve (size 25 mm) under pulsatile flow in a curved aorta (180, 
HEMOLYSIS BJORK-SHILEY TILTING DISC VALVE (continued) 
Position Model U 	LDH 	Hgb 	Hapt 	Other Remarks Ref# 
M std 	425.5+124.8 U/L 	14.32+1.34 	31.0 mg/dl 85% of 33 had hemolysis 198 
(Z0-450)* g% 	 (30-180)* 
(13.5-18.0)* 
A NA 	234 IU/L 	14.5 g/100 ml 	96 mg/dl 7/10 had chronic hemolysis 218 
(range 178-287) (range 13.1-16) 	(range 15-284) 
(90-215)* 	(12.5-18)* (170-300)* 
double NA 	> normal 	NA 	reduced or 
absent 
14/16 patients had hemo- 
lysis 
220 
A std 	195 U/L 	15.1 g% 	NA 
(131)* (14.9)* 
74 had mild to moderate 
hemolysis 
222 
M 199+52 U/L 	normal 	18/40 	plasma hgb 
<normal 5 mg% 




M std 	NA 	 NA 	NA 42% had hemolysis 295 
double std 	NA 	 NA 	NA 85% of 38 had increased 420 
LDH 
A,M std 	510 U/L 	NA 	reduced in 13/16 had hemolysis 105 
(452)* 10,absent in 3 
A,M C-C 	NA 	 NA 	NA 37/37 had mild hemolysis 1 
A std 	362 units 	NA 	37 mg% 	plasma hgb 
	
(range 190-1080) (range 4-164) 57 mg% 
LDH increased in most;hapt 
normal in half of the 
7 




THROMBOEMBOLIC COMPLICATIONS : BJORK-SHILEY TILTING DISC VALVE 
Position Model# Patient 
Ratio 
Rate 	 Deaths 
% per pt-yr 
Anticoagulation Remarks 	 Ref # 
double both 15/164 3.7 6 dicoumarol 11 TEC'sduetoinade- 	41 
quate anticoagulation; 
5 thrombosed valves 
double std 1/25 1.0 1 dicoumarol 1 thrombosed valve due 	41 
to discontinuation of 
anticoagulation 
double C-C NA 0.9 NA dicoumarol 1 thrombosed valve 	41 
A std 5/106 NA NA warfrin 48 
A std NA NA 2 all patients 7/121 had large thrombi 	47 
on struts and disc; only 
1/7 had adequate anticoagulation 
M std 13/72 NA 16 discoumarol majority of the 16 	42 
deaths were due to TEC's 
A,M std 25 patients NA 2 heparin and 
coumadin 
2/25 had massive 	45 
thrombus across 
minor orifice causing 
death 
M std 8/81 NA NA all patients 21 
M std 5/109 NA 0 warfarin 54 
A std 8/77 5.6 3 all patients 2 thrombosed valves 	53 
std 12/127 NA 3 NA deaths caused by 	52 
thrombosed valves 
double std 2/23 8.2 0 warfarin 105 
THROMBOEMBOLIC COMPLICATIONS MORK- SHTLEY TTTLTING DISC VALVE (continued) . 
Position Modell 	Patient Rate Deaths Anticoagulation Remarks Ref it 
Ratio % per pt-yr 
A,M & 
double 
std. 	& C.C. 10 years experience 
30/1800 valves had 
thrombotic occlusion 
11 
std. 	NA 4.4 0.4%/pt-yr NA 193 patients 11 
M C.C. 	NA 1.2 0 NA 98 patients 11 
M std. 	5/42 NA 1 all patients 1 thrombosed valve 
caused death 
18 
A std. 	2/57 NA 0 all patients 8 
A std. 	36/379 NA 5 coumadin in addition there 401 
were 8 thombosed valves; 
7 caused deaths 
std. 	17/167 NA 4 coumadin in addition there 401 
were 3 thrombosed valves; 
2 caused deaths 
double std. 	12/97 NA 0 coumadin in addition there 401 
were 5 thrombosed valves; 
4 caused deaths 
A,M & 
double 
std. 	30/435 1.8 16 warfrin 13 valves were 
thrombosed; 11 caused 




conducted at a steady flow rate of 25 1/min, (277, 352, 353, 417, 20). 
The measurements with the spherical disc valve identified a zone of 
stagnation about 20 mm wide near the aortic face of the disc. The 
average velocities in the major and minor outflow regions were around 
100 and 25 cm/s, respectively, and the corresponding peak shear stresses 
adjacent to the sewing ring were approximately 700 and 150 dynes/cm2 . A 
maximum wall shear stress of 1390 dynes/cm 2 was measured. With the 
convexo-concave valve the region of stagnation was observed to be 10 mm 
wide, and the average velocities in the major and minor outflow regions 
were around 90 and 40 cm/sec, respectively. Peak shear stresses on 
surfaces adjacent to the sewing ring in the major and minor outflow 
regions were about 500-600 and 300-350 dynes/cm2 , respectively. The 
convexo-concave valve does, however, direct relatively high flow from 
the major outflow region towards one of the sinuses of Valsalva 
depending on its orientation. Wall shear stresses on the order of 1750 
dynes/cm 2 were observed on the sinus wall towards which the high flow 
was directed. Turbulent measurements with both models indicated 
turbulent shear stresses on the order of 500 to 2000 dynes/cm 2 
 immediately downstream (3 to 15 mm) from the valve. 
(d) Correlation  
The in vivo and in vitro pressure measurements indicate that in the 
larger sizes and under resting conditions the pressure drop 
characteristics of the Bjork-Shiley valve are quite satisfactory. 
However, under exercise conditions and/or in the smaller sizes the valve 
could become mild to moderately stenotic. This is especially true in 
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along the sewing ring in that region. 	As has been observed in the 
recovered valves, the combination of thrombus formation and tissue 
overgrowth can produce catastrophic results. 
The smaller region of stagnation, and the better distribution of 
flow between the major and minor orifices observed with the 
convexo-concave valve, may hopefully reduce the problems of thrombus 
formation on the outflow face of the disc, and excess tissue growth 













IN I MG 
mmHg 
PC 	CI 
mmHg -min 1/m2  
VA 2 
cm 
41 NA 	2.4 0.77 	2 75 5.11 .92 
287 








NA 46 	NA 0.81 
(28-70) 77 
NA 45 	NA 0.8 
(27-70) (0.5-1.1) 
16 
47.6+12.7** 36+17.4** 	NA 0.69+.11 ** 
(N=4) 
287 
31 NA 	2.98 1.05 	3 52 6.56 1.25 
(22-41) (2.9-3.1) (.82-1.2) (42-63) (5.86-7.03) (1.18-1.31) 
294 
33 NA 	3.5 1.21 
(16-53) (2.6-5.6) (.83-1.56) 125 
NA 25 	NA 1.10 
291 
NA 32 	NA 0.98 
77 
NA 28 	NA 1.1 
(5-57) 16 
1.17+0.14** 









(27-38) 5.54 1.02 
(3.4-7.7) (1.07-1.9) 	294 
22 NA 	3.6 1.56 
(19-25) (3.3-4.0) (1.36-1.68) 
125 
NA 18 	NA 1.20 
291 
NA 12 	NA 1.1 77 
NA 22 	A 1.3 
(10-42) (0.9-1.8) 























IN VIVO PRESSURE DROPS: LILLEHE1-KASTER AORTIC VALVE  








LILLEHEI-KASTER MITRAL VALVE 
Exercise 




















23 2 	 9+4.2" NA 	1.45+.07 291 
1 	 21 4.95 	1.08 293 
25 1 	 NA NA 	1.1 77 
2 	 7 1.62 	1.39 1 1.12 293 
(6-8) ** (1.32-1.91) 
27 9 	 8.33+5.2 NA 	1.81+.81 291 
8 	 8 NA 	1.6 77 
(4-14) (1-2.3) 
4 	 7.5 2.38 	1.59 1 18 4.0 1.77 293 
(4-13) (2.06-2.63)(1.56-1.63) 
2 	10.1 2.9 	1.8 294 
(7.6-12.5) (2.4-3.3) 	(1.61-1.98) 
29 7 	6.57+2.7** NA 	1.87+.42 291 
14 	 7 NA 	1.8 77 
(3-11) (1.0-2.8) 
1 	 6.5 4.11 	2.13 293 
4 	 5.9 3.1 	1.9 294 
(6-10) (2.4-3.0) 	(1.56-2.19) 
32 7 	7+3.2 ** NA 	2.33+.74 
291 
77 
2 	 S NA 	2.7 
(3-7) (2.6-2.7) 
3 	 4.3 3.5 	3.02 1 14 3,E 2.89 293 
(3.5-5) (2.8-4.1) 	(2.74-3.44) 
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Table 41b 
Comparison of In Vivo valve areas of Bjork-Shiley and Lillehei-Kaster mitral 
valves. 
Name of Valve 	 Tissue Annulus 	 N 	 VA 
Size 
2 
mm 	 cm 
Lillehei-Kaster 27 23 1.70 
Lillehei-Kaster 29 26 1.85 
Bjork-Shiley 27 & 29 63 2.24 
*obtained from data presented in Tables 35 and 41a. 
TABLE 42 




Model 	 Ali 








RV 	 Ref 	It 
cm /stroke 
19 5-7.2 0.85 419 p. 181 
21 34.5(peak) 3.5 N/A 307 
21 5-7.2 1.19 419 p. 181 
23 28.0(peak) 4.3 N/A 307 
23 5-7.2 1.57 419 p. 181 
25 30.0(peak) 5.5 N/A 307 
25 5-7.2 2.00 419 p. 181 
*27 4.1 20 3.18 177 
27 5-7.2 2.49 419 p. 181 
27.5 25.0(peak) 6.0 N/A 307 
*steady flow data 
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death. Thrombosed valves have been recovered from both aortic and 
mitral positions. Thrombus formation mainly occurs on the outflow face 
of the disc. Thrombosis on both downstream and upstream faces has also 
been occasionally observed. In some instances the thrombus has formed 
in such a manner that the disc opening angle has been reduced. In other 
instances, the thrombus has frozen the disc in an open position. 
Problems of tissue overgrowth have not been specifically mentioned but 
it seems to occur together with thrombosis along the downstream sewing 
ring of the minor orifice region. 
(c) In Vitro Results 
Tables 42 and 43 indicate that the Lillehei-Kaster valve has 
reasonable in vitro pressure drop characteristics especially in the 
moderate to larger valve sizes. Calculated valve areas ranged from 0.85 
to 3.94 cm2 for the size 19 to 33 mm aortic and mitral valves. A study 
conducted on 30 mm Lillehei-Kaster and 29 mm Bjork-Shiley mitral valves 
tends to indicate that these valve designs have similar regurgitation 
characteristics (413). 
Flow visualization studies have been conducted under pulsatile flow 
conditions in both aortic and mitral chambers (199, 211, 236, 305). 
Wright and Temple conducted their studies in a curved aorta (199). When 
the valve (25 mm size) was placed so as to open towards the inside of 
the aortic curve, about 100 ms into systole a small jet was formed which 
flowed tangential to the inside curve of the aorta. When the valve was 
oriented towards the outer curve of the aorta, clockwise circulating 
vortices were set up 4.5 cm distal to the valve. In addition a narrow 
jet formed in the aortic curve. In this orientation the flow through 
the major orifice impinged onto the aortic wall and flowed along the 
wall. In the mitral position (29 mm valve size) a large, two 
dimensional vortex formed which dominated the left ventricle and may 
have aided valve closure. In this study it was noted that the flow 
patterns produced by the Lillehei-Kaster and Bjork-Shiley valves were 
quite -similar. Dellsoerger and dieting (305) observed a region of 
stagnation underneath the downstream face of the disc with a 29 mm 
Lillehei-?Caster valve (mitral), during a major portion of diastole. A 
careful study should indicate similar qualitative findings in the aortic 
position during systole, as observed with the Bjork-Shiley aortic valve. 
Using hot-film shear probes Tillman has measured "wall" (ie: 
surface) shear stresses along the metal orifice ring in the major and 
minor orifices (365). The experiments were conducted under pulsatile 
flow conditions in the aortic position. He observed peak shear stresses 
of 120 and 40 dynes/cm2 in the major and minor orifices, respectively, 
during systole. Hwang, et al., (419 p. 91) have made velocity and 
shear stress measurements about 40 mm downstream from a 27 mm aortic 
valve a cardiac output of 3.8 1/min. These measurements indicated a 
peak turbulent shear stress of about 175 dynes/cm 2 . If measurements 
were made closer to the valve, it is expected that the turbulent shear 
stresses measured would be on the order of 500 to 2,000 dynes/cm2 , as 
observed with the Bjork-Shiley valve (277, 351, 352, 411, 417). Since 
the flow field created by the Lillehei-?Caster valve is quite similar to 
that created by the Bjork-Shiley valve, it is expected that it will 





The in vivo and in vitro pressure measurements for this prosthesis 
do not predict the results. The in vivo hemodynamics indicate that the 
Lillehei-Kaster prosthesis is moderately stenotic in the medium and 
large sizes and very stenotic in the small sizes; results are comparable 
to those observed with the Starr-Edwards ball valves. The in vitro 
 results indicate that the pressure drop characteristics of this 
prosthesis are quite similar to those observed with the Bjork-Shiley 
prosthesis. The most probable reason for this result is the observed 
clinical finding that the Lillehei-Kaster prosthesis does not open 
completely in vivo, while it does so in vitro in pulse duplicator 
systems. This performance is probably due to some complex "aerodynamic" 
lift phenomena occurring in the in vivo situation which we are at 
present unable to simulate in vitro. Sabbah and Stein have shown that 
at cardiac outputs of less than about 1 to 2 1/min with the valve 
oriented to open against gravitational forces, less than full opening is 
observed with the Lillehei-Kaster and Bjork-Shiley valves (208). No 
such effect is seen when the valve is oriented to open with gravity. 
Flow visualization studies and the limited velocity and shear 
stress measurements indicate that sub-lethal and/or lethal damage could 
occur to the endothelial lining of the vessel wall, red cells and 
platelets. Therefore, hemolytic and thromboembolic problems are 
predictable with this prosthesis. In vivo and in vitro studies show 
that most of the flow through the valve occurs through the major outflow 
121 
9. 
HANCOCK PORCINE VALVE BIOPROSTHESIS 
(a) Valve Description 
The Hancock porcine bioprosthesis, prepared by the Stabilized 
Glutaraldehyde Process ("SGP") has been in clinical use since 1970. 
Porcine aortic valves preserved by the "SGP" process are sutured to a 
Dacron cloth-covered flexible polypropylene stent. A radio-opaque 
Stellite metal ring encircles the stent and helps maintain orifice shape 
and proper leaflet coaptation. Model 242 is used for aortic valve 
replacement while model 342 is used in the mitral and tricuspid valve 
areas. These models differ only in the shape of their sewing rings. 
The Hancock Modified Orifice aortic bioprosthesis (HMO-250) differs 
from the other two models by having replaced the right coronary leaflet, 
which contains a portion of septal endocardium with a non-coronary 
leaflet of an appropriate size. This valve modification was 
accomplished in an attempt to increase the effective flow orifice for 
use in patients with a small aortic annulus.' The first clinical Implant 
of a HM0-250 bioprosthesis was in October 1976. 
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Size mm  












mmHg ref#  
CI 	 VA

















































PG 	 CI 
, 
mmHg 	A'-min-1 /m 2  
VA 
cm2  
MC 	 PO 	 CI 	 VA 2
1 
mmHg 	mmHg i-min
-1 /m2 	cm 	
refit 
23 2 21.1+0.4** NA 1.3 345 
25 5 17.8+5.2** NA 1.46+0.18** 345 
27 8 13.1+3.2** NA 1.89+0.41 ** 345 
1 12 2.4 NA 325 
29 8 12.0+2.4** NA 2.05+0.27 ** 345 
5 5 2.8 NA 325 
(4-8) (2.3-3.3) 
20 5.2 NA 2.1 323 
(0-10) 
31 8 10.3+3.4** NA 2.15+.37** 
345 
2 5 2.4 NA 325 
12 2.3 NA 2.9 323 
(0-8) 
33 9 8.7+2.2** NA 2.47+0.35** 
345 
4 5 2.9 NA 325 
(4-6) (2.4-4.0) 
10 2.5 NA 2.9 
323 
(0-10) 
** + SD 
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Sizes and Dimensions 
Size Sewing Ring 	Valve Height 	Internal Stent 
Diameter(mm) (mm) 	Diameter(mm) 
Internal Stent 





19 19 15 11 16.0 2.01 
21 21 16 12 18.0 2.54 
23 23 18 13 20.0 3.14 
25 25 19 14 21.8 3.73 
27 27 20 16 22.5 3.98 
29 29 21 17 24.3 4.64 
31 31 23 17 26.2 5.39 
33 33 - 18 27.9 6.11 
35 35 - 20 29.8 6.97 
(b) In Vivo Results 
Since the Hancock valve is the grandfather of the tissue valve 
bio-prostheses, there are many articles in the open literature on its 
long-term clinical performance. The standard model aortic valve has 
calculated VA's of 0.97 to 1.8 cm2 for valve sizes of 19 to 27 mm (Table 
146). In the mitral position calculated VA's ranged from 1.3 to 2.9 cm 2 
 for valves sizes of 23 to 35 mm (Table 48). The modified orifice aortic 
valve had VA's of 0.89 to 1.75 cm2 for valve sizes of 19 to 25 mm (Table 
47). Comparing the results in Tables 46 and 47, it is not immediately 
obvious that the modified orifice valves are less stenotic than the 
standard model valves. As stated by Rossiter, et al., (338) the 
hemodynamic differences between the two valve types are small, and the 
putative clinical advantages inherent in the use of the modified orifice 
valve remain to be completely defined. Both designs of Hancock valves 
are, however, more stenotic compared to the Ionescu-Shiley pericardial 
valve. Clinically significant hemolysis is not a major problem with 
TABLE 50 
















19** 250(M0) 49.21 19.98 0.92 0.7(@100 min
-1
) 413 
19* * 242 74.04 19.98 0.75 0.8(9100 min
-1
) 413 
19** 250(MO) 29.9 16.6 0.9 
21** 250(MO) 31.49 19.98 1.15 1.1(9100 min 1 ) 413 
21** 242 46.15 19.98 0.95 1.0(@100 min-1 ) 413 
23** 250(MO) 25.03 19.98 1.29 1.0(9100 min
-1
) 413 
23** 242 31.49 19.98 1.15 1.4(@100 min-1 ) 413 
25** 250(MO) 17.34 19.98 1.55 1.1(9100 min
-1 
 ) 413 
25 342 25.82 19.98 1.27 1.3(9100 min-1 ) 413 
25** 250(M0) 10.7 16.6 1.64 200,168 
27 342 18.02 19.98 1.52 1.3(9100 min
-1
) 413 
29** 242 13.00 19.98 1.79 1.2(@100 min-1 ) 413 
29 342 7.39 16.6 1.98 200,168 
29 342 N/A '100-300(Q) 'A, 	1.8 201 
29 342 N/A 5-7.2 N/A 1.79 419 p 181 
31 342 11.18 19.98 1.93 1.8(@100 min
-1
) 413 
33 342 12.44 19.98 1.83 1.4(9100 min
-1
) 413 
33 342 N/A 5-7.2 N/A 2.41 419 p 181 
**studied in the mitral position 
TABLE 51 
HEMOLYS1S HANCOCK PORCINE VALVE 
Position Model # 	LDH Hgb Rapt Other Remarks Ref# 
M,T 204+52 IU/L NA 94+52 mg% plasma hgb 2/22 had anemia 337 
(130-360)* (50-250)* .58+1.55 22/22 had mild hemolysis 
(0-6)* 
double NA NA NA one pt had severe hemolytic 
anemia when the struts 
were bent inward 
330 
M 565 U/L NA NA red cell damage by dacron- 
covered sewing ring & 
stents-one pt. 
383 
M NA NA NA no clinically significant 





IRROMBOEMBOL1C COMPLICATIONS ; 
	 HANCOCK PORCINE VALVE 
Position 	Model# 	Patient 	Rate 	 Deaths 	Anticoagulation 	Remarks 	 Ref # 
Ratio % per pt—yr 
A 	 1/65 	 NA 	 0 	none 	 193 
A,14,T 	 NA 	 NA 	6(early) 	none 	 37Opts studied;9/34 194 
3(late) valves recovered had 
M 18/243 NA NA 
M 1patient NA 1 
M,T 1/11 NA NA 
M 3/33 NA 1 
T 1patient 
M 1patient NA 1 
A,M 26/211 NA 7 
A,M 12/193 NA NA 
A,M 0/25 NA NA 
M 20/272 4.1 NA 
thrombosis on outflow side 
of valve; all 9 were mitral 
prostheses. 
NA 	 195 
none 	 small thrombi on 	329 
valve cusps 
none 	 333 
warfarin for 	thrombus on 2 cusps 	324 	 QJ 
 1--, 
first 6 wks. and on ventricular LA 
aspect of mitral 
valve caused death 
fibrin deposition 	336 
on cusps 
none 	 large muscle shelf 	332 
caused thrombus on 
sewing ring & atrial 
wall 
few on warfarin 6 early TEC's 	 327 
(one month) 
none 	 323 
first 8 weeks 	 321 
first 3 months 	2 thrombosed valves 	319 
THROMBOEMBOLIC COMPLICATIONS : 	 HANCOCK PORCINE VALVE (continued) 
Position Modell Patient 
Ratio 
Rate 














A 18/481 1.8 0 
A modified 
orifice 
4/156 4.4 0 
A NA 1.7 1 
M NA 2.6 1 
double NA 1.6 1 
A 2/124 NA 0 
A 3/60 1.28 0 
M 14/125 2.87 3 
double 2/36 1.37 0 
Anticoagulation 	Remarks 	 Ref # 
first 6-8 weeks 	 377 
none 	 all TEC's in patients 	373 
with atrial fibrillation 
none 	 376 
none 	 338 
none 	 338 
first 6 weeks 	 335 	 1— 
l...) 
,4 
first 12 weeks 	 335 
first 12 weeks 	 335 
none 	 325 
80% of pts had none; 	 444 
rest had anticoagulation 
for first 3-6 months 
all patients with 	 444 
atrial fibrillation 
all patients with 	 444 
atrial fibrillation 
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Flow visualization studies (141, 180, 199, 236) indicate that the 
flow that emerges from the Hancock valves, standard and modified 
orifice, is jet-like. Schramm, et al., (141) in their study showed that 
there was no reattachment of the jet. At a steady flow rate of 181/min 
they observed a peak jet velocity of 180 cm/s with a size 25 modified 
orifice valve. Wright (180, 199) in his studies observed a vortex swirl 
in addition to the jet. High speed photography by Rainer et al., (209) 
showed that there was high frequency fluttering of the muscle-shelf 
leaflet during end-systole, with the aortic Hancock valve. No published 
velocity and shear stress measurements on the Hancock valve were 
encountered in our literature review. The primary reason for this being 
the company's past "policy" of not providing valves free of charge to 
engineering investigators. It is the only company which maintained such 
a "policy." It is our opinion, however, that the velocity and shear 
stress measurements downstream from the Hancock valves will be quite 
similar to those obtained with Carpentier-Edwards porcine valves. 
Gabbay et al., (200) state that there is no difference in pressure drop 
characteristics between the Carpentier-Edwards and modified orifice 
Hancock valves of corresponding sizes. 
(d) Correlation 
The in vivo and in vitro pressure gradient information clearly show 
that the Hancock porcine valves are stenotic especially in the smaller 
sizes. Patients with these valves wil not be able to lead very active 
lives due to large gradients across these valves under exercise 
conditions. The stenotic nature of the valve is in part due to the 
10. 
CARPENTIER-EDWARDS PORCINE VALVE 
(a) Valve Description 
The Carpentier-Edwards bioprosthesis is composed of porcine aortic 
valve leflets preserved in a buffered gluteraldehyde solution and 
mounted on a man-made flexible stent. The frame is made from a light 
weight corrosion resistant alloy called Elgiloy (cobalt-nickel alloy). 
The metal frame is covered with porous knitted Teflon cloth. Model 2625 
is used for aortic valve replacement while model 6625 is used for mitral 
valve replacement. These models only differ in the shape of their 
sewing rings. The Carpentier valve has been in clinical use since 1975. 
Sizes and Dimensions 








21 21 16 18 2.40 
23 23 17 20 3.24 
25 25 18 22 4.19 
27 27 20 23 4.34 
29 29 21 25 5.11 
31 31 22 27 5.93 
33 33 22 29 6.80 
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TABLE 54 





refit 1" MG mmHg PG 	 CO mmHg 	k--min-1  VA cm2 N MC mmHg PG 	 CO 1 mmHg 	t-min VA 2 I cm 
27 3 7 4.2 1.68 2 20 8.8 2.41 241 
(7) (3.6-5.0) (1.44-1.82) (19-21) (8.4-9.1) (2.06-2.77) 
29 7 6.7 4.0 1.94 5 14 6.6 1.82 241 
(3-10) (3.2-6.5) (1 54-3.67) (9-32) (4.2-11.3) (1.48-2.67) 
31 3 5 4.4 2.79 3 9.3 6.9 3.41 241 
(4-6) (3.7-4.8) (2.23-3.81) (6-14) (5.2-9.1) (2.89-4.83) 
33 2 4.5 5.7 3.09 1 10 5.8 2.39 241 
(3-6) (3.8- 7.5) (2.28-3.9) 





AN 	 CO 
mmHg t/min 
VA 	 RV 
2 
cm 	 cm/stroke 
TABLE 55 



















0.8(@70 min-1 ) 
1.2(@70 min-I ) 





Average turbulent shear stresses during peak velocities were estimated 
to be on the order of 4200 dynes/cm 2 . Yoganathan, et al., (349, 425) 
measured the velocity field downstream from a #27 aortic valve at steady 
flow rates of 10 and 25 1/min. The velocity profiles obtained were jet 
like, and also showed a region from flow separation and recirculation 
near the walls immediately downstream from the valve sewing ring. The 
effects of the jet were observed even 60 mm downstream from the valve. 
The turbulent shear stresses were on the order of 1000-3000 dynes/cm2 
 and wall shears on the order of 200 to 600 dynes/cm2 . In addition,
Yoganathan, et al., (349, 425) have photographed the opening and closing 
motion of the valve leaflets under pulsatile flow (sizes 27, 25 and 21). 
It was observed that the leaflets did not open symmetrically or 
reproducibly. 	The leaflets opened less at lower cardiac outputs (2.5 
1/min) compared to normal cardiac outputs (5.0 1/min). 	It was also 
observed that the muscle-shelf leaflet was the last to open and the 
first to close. The valve leaflets only opened to about 50% of their 
approximate primary orifice areas. Gabbay, et al., (200) have made 
similar observations. High speed photography by Rainer, et al., (209) 
indicated that the leaflet with the muscle shelf exhibited high 
frequency vibrations during end systole. 
(c) Correlation 
The in vivo and in vitro pressure drop data indicate very clearly 
that this porcine valve design is also stenotic especially in the small 
sizes. Patients with these valves would find exercise strenuous and 
difficult. The in vitro valve photography showed that the leaflets do 
not open adequately, especially at low flows. This is therefore one of 
TABLE 58 
THROMBOEMBOLIC COMPLICATIONS ; CARPENTTER - EDWARDS PROCINE VALVE 
Position Modell Patient 
Ratio 
Rate 
% per pt-yr 
Deaths Anticoagulation Remarks Ref 
A 2625 14/12,650 NA NA NA 10 had thrombosed 
valves 
245 
M 6625 15/12,838 NA NA NA 8 had thrombosed 
valves 
245 
A,M NA 0/55 NA 0 first 3 months 386 
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IONESCU -SHILEY PERICARDIAL VALVE 
(a) Valve Description 
The Ionescu-Shiley pericardial xenograft consists of three equal 
cusps which are mounted on a man made symmetrical titanium stent covered 
with Dacron cloth. The pericardial tissue which is obtained from the 
calf is treated and fixed in a buffered gluteraldehyde solution. The 
valves are then subsequently stored in 4% buffered formaldehyde to 
insure sterility. Although the pericardial valve was first used in 
clinical trials in 1971, it was first released for general use in the 
U.S.A. in 1976 as the Ionescu-Shiley prosthesis. The essential 
dimensions of the different size Ionescu-Shiley valves as obtained from 
Shiley laboratories, Inc., are given below. The valve has a universal 
sewing ring. 
Size and Dimensions  









15 15 12 11.4 1.02 
17 17 13 13.4 1.41 
19 19 14 15.4 1.86 
21 21 15 17.4 2.38 
23 23 17 19.4 2.96 
25 25 18 21.4 3.60 
27 27 19 23.4 4.30 
29 29 20 25.4 5.07 
31 31 22 27.4 5.90 
33 33 24 29.4 6.79 
*4- SEM 
Rest 

























 3.1+0.2(CI) * 1.6+0.1* 	 NA 17.5+0.1 4.4+3.2(CI) * 2.1+.1 301 
5 0 NA 2.1 	 6 1.0 NA 2.4 313 
3.3 NA 5.2(CO) 2.7 299 
(3.4-4.2) (3.8-6.5) 




23 & 25 	4-23 
2-25 
27 	 1 
2 
31 	 1 
(b)In Vivo Results 
In vivo VA's of 0.9 to 3.2 cm
2 
were calculated for aortic valve 
sizes of 19 to 31 mm (Table 59). Mitral VA's varied from 1.2 to 2.4 cm 2 
 for valve sizes of 25 to 29, (Table 60). These results also indicate 
that the calculated VA's increase under exercise conditions (ie: 
increasing cardiac output). Thromboembolic events have been documented 
for this valve with TEC rates of 0.42 to 3.34% per pt. yr. (Table 64). 
No thrombosed valves have been documented. Articles published to date 
indicate that this valve could cause mild to moderate hemolysis even 
though the body can compensate for it. Since this valve has been in 
wide spread use only during the past four to five years the literature 
is incomplete. Dr. Harrison has observed excess fibrotic tissue on the 
sewing rings and up the outflow bases of the leaflets of recovered 
Ionescu-Shiley valves (439). A similar observation has been made by Dr. 
Trusler on a valve recovered from a 3 year old child (341). He also 
observed early calcification of the leaflets. 
(c)In Vitro Results 
Tables 65 and 66 indicate calculated VA's of 1.49 to 2.86 cm 2 for 
the size 21 through 31 valves. The calculated VA's for the 
Ionescu-Shiley valve in the mitral position obtained by Wright (413) are 
lower than those obtained by Gabbay and his co-worker (168, 200) and 
Walker, et al., (201). Results obtained in our laboratory (425) tend to 
agree better with those of Gabbay, et al., and Walker, et al. 
Regurgitation volumes are higher than for the porcine type valves. High 
speed photography has shown that the leaflets of the Ionescu-Shiley 
valves open uniformly and do not flutter (209). Photography studies in 




















IN VITRO PRESSURE DROPS: IONESCU-SHILEY MITRAL VALVE 
19 ISUD 18.25 16.6 1.26 168,200 
21 ISUD 24.64 19.98 1,30 2.1(8100 min
-1
) 413 
23 ISUD 17.11 19.98 1.56  3.4(8100 m1n
-1
) 413 
25 ISUD 17.56 19.98 1.54 3.1(@100 min
-1
) 413 
25 ISUD 7.7 16.6 1.93 168,200 
27 ISUD 14.58 19.98 1.69 5.2(8100 min-1 ) 168,200 
29 ISUD 9.27 19.98 2.12 4.8(@100 min
-1
) 413 
29 ISUD 3.3 16.6 2.96 168,200 
29 ISUD " 	1.5-6.0 q, 100-3000) 't, 	2.5 201 I--, 






HEMOLYSIS IONESCU -SHILEY PERICARDIAL VALVE 
Position Model # 	LDH 	Hgb 	Hapt 	Other Remarks Ref# 
A 402 1U/L 	13.8 g% 	15 mg/d1 10/10 had chronic hemolysis 218 
(range 294-580)(range 12.5-16)(range 10-28) 
(90-215)* 	(12.5-18)* 	(170-300)* 
M 
	
306.2 IU/L 	13.7 g% 	26.5 mg/d1 
(range 285-333) 	(range (range 12-53) 
8/8 had mild to moderate 
hemolysis 
300 
(90-200)* 	12.8-14.6) 	(170-300)* 
(12.5-18)* 
M normal 	NA 	normal 12 pts had no clinically 
significant hemolysis 
18 
A,M NA 	 NA 	NA 24 pts had no clinically 
significant hemolysis 
301 
* normal values 
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up the outflow faces of the leaflets. The region of flow separation 
observed adjacent to the valve leaflets could in addition lead to a 
build up of thrombotic, fibrotic and/or calcific materials on the 
outflow surfaces of the leaflets, as observed with the Hancock porcine 
valves. The wall shears could cause sublethal damage to endothelial 
tissue, while the turbulent shear stresses could lead to sublethal 
and/or lethal damage to blood elements. Such damage could lead to 
hemolysis, and thromboembolic problems as observed clinically. 
TABLE 65 





























19 6 13.8 3.2 1.5 131 p. 	26 
(0-30) (2.7-3.3) (1.2-1.6) 
3 11.0 3.1 1.38 130 
21 2 9.0 4.95(CO) 1.15 130 
12 5.2+5.3** 3.9+0.9** 2.7 +1.5** 12 12.1+6.9** 6.8+1.2** 2.2+1.0** 	129 
(CO) (60) 
15 6.0 2.7 2.1 131 p. 	26 
(0-26) (1.4-3.6) (1.0-4.7) 
4 1.0 3.25 NA 4 3.0 4.37 NA 	131 p. 	10 
(0-3.0) (2.7-3.7) (0-6.0) (4.1-4.7) 
23 5 1.60 3.3 2.26 130 
11 3.2+3.8** 4.4+1.0** 3.6+1.7** 8 8.7+4.7** 7.0+2.1** 2.8+1.5** 	129 
(CO) 
J4 2.2 3.0 2.4 131 p. 	26 
(0-6) (2.0-4.0) (1.25-3.47) 
7 1.0 3.27 NA 7 2.6 4.6 NA 	131 p. 	10 
(0-4.0) (2.9-3.5) (0-8.0) (4.0-4.9) 
25 14 2.07 3.21 2.26 130 
5 3.4+1.8** 4.0+0.8** 3.0+1.5** 3 4.9+4.6** 6.6+0.7** 4.6+3.2** 	130 
(CO) (CO) 
30 2.6 3.0 2.7 131 p. 	26 
(0-11) (2.0-4.0) (1.5-5.5) 
11 2.0 3.36 NA 5 6.3 4.92 
NA 	131 p. 	10 
(0.50) (2.5-3.9) (0-24.0) (3.3-6.0) 





 ref # 
TABLE 66 























































27 20 1.2 3.3 3.1 131 p. 26 
(0-4.0) (1.8-4.5) (1.68-3.67) 
10 1.24 3.6 3.30 10 1.48 4.0 3.4 131 p. 54 
** ** ** ** ** ** 
5 1.9+0.6 3.6+0.4 2.1+0.4 3 3.6+2.0 6.4+0.9 3.5+1.6 129 1-. 
(CO) (CO) con In 
29 33 1.2 2.7 3.1 131 p. 26 
(0-9.0) (1-4.8) (0.98-4.4) 
5 0.55 3.8 4.0 5 0.70 4.2 4.1 131 p. 54 
** ** ** ** ** ** 
16 1.8+0.8 3.6+0.7 2.8+1.0 13 3.6+2.0 6.4+0.9 4.4+2.2 129 
(CO) (CO) 
** ** ** ** ** ** 
8 2.46+1.06 2.5+0.6 2.8+1,3 8 7.0+3.2 4.0+0.9 3.2+1.3 391 
31 9 3.4 2.9 2.7 131 p. 26 
(0-8.0) (1.4-4.3) (1.0-5:2) 
4 0.3 4.1 4.57 4 0.4 4.4 5.1 131 p. 54 
** ** ** ** ** * * 
3 1.6+0.4 4.6+0.8 3.1+0.9 3 3.2+1.3 8.4+0.9 4.3+1.5 129 
(CO) (CO) 
** + SD 
TABLE 67 


















19 5-7.2 1,4 419 p 181 
21 5-7.2 1.77 419P 181 
23 5-7.2 2.19 419P 181 
25 5-7.2 2.66 419P 181 
25 4.0 '%., 	5.3 20 3.23 425 
27 5.4 't, 	7.5 30 4.17 425 
*27 '1,3.8 20 3.31 177 
27 4.0 13.3(@50 min
-1
) 237 
27 5-7.2 3.16 419P 181 
*steady flow data 
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(c) In Vitro Results 
In vitro flow studies indicate that this valve has the lowest 
pressure drops of any of the prostheses in current clinical use. A 
recent study by Dellsperger, et al., (237), however, indicate that this 
valve may have significant a regurgitant volume at low heart rates and 
low cardiac outputs. 
Flow visualization studies in aortic and mitral chambers under both 
steady and pulsatile flow indicate smooth central type flow downstream 
from the valve (141, 137, 211, 236, 306). Initial velocity and shear 
stress measurements have been made by Yoganathan, et al., with size 27 
and 25 aortic valves (372, 415 p. 295, 425). The measurements were 
made under steady flow rates of 10 and 25 1/min. The velocity 
measurements indicate that the flow field that emerges from the valve is 
centralized with low turbulence intensities. The measurements showed a 
region of flow separation immediately downstream from the sewing ring 
and adjacent to flow channel walls. Wall shear stresses on the order of 
50 to 600 dynes/cm 2 were measured together with estimated turbulent 
shear stresses of 100-600 dynes/cm 2 . Velocity measurements have not 
been made close to the pivoting mechanism of the valve. Schramm, et 
al., under steady flow conditions have also observed flow separation 
occurring from the downstream sewing ring (141). They state that the 
flow separation generates a circular dead water region which surrounds 
the main flow. Studies in our laboratory (425) and by Rainer, et al., 
(451) indicate asynchronous closing of the two leaflets in pulsatile 
flow. We have also observed that particles of dirt in the blood analog 
fluid cause sticking of the valve leaflets. 
THROMBOEMBOLIC COMPLICATIONS : 
TABLE 70 
ST. JUDE BI-LEAFLET VALVE 
Position Modell Patient Rate Deaths Anticoagulation Remarks Ref II 
Ratio % per pt-yr 
A,M 1/88 NA 0 79/88 on warfarin 129 
M 0/23 0 coumadin 125 
A 0/25 0 coumadin 125 
A,M 8/65 NA I none; on plate- 
let inhibiting 
agents only 
4 valves had dys-
function due to 
thrombosis 
132 p 7 
A,M 6/115 NA 2 NA 132 p 31 
A 0/71 0 acenocoumarol or 132 p 45 
1 /50 NA NA 
aspirin and dipy- 
ridmole 132 p 45 
double 1/29 NA NA 132 p 45 
12/1341 1.2 NA majority on 
coumadin 
4 thrombosed valves 132 p 59 
A 12/1873 .9 NA majority on 
coumadin 
132 p 59 
A 0/24 - 0 NA 132 p 72 
M 0/15 - 0 NA 132 p 72 
M 2/82 NA NA all patients 132 p 25 
A,M 0/24 - 0 coumadin 132 p 6 
A 0/71 - 0 acenocoumarol 131 p 24 
M 1/50 .23 NA acenocoumarol 131 p 24 
A,M 0/87 - 0 coumadin 2 yr follow up 132p.6 
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(d) Correlation 
The in vivo and in vitro results indicate clearly the superior 
pressure drop characteristics of the St. Jude prosthesis. This is a 
tremendous advantage for patients who lead active lives, as well as for 
children and adults with small valve annuli (129, 130; 131 p. 	10, 26 & 
54; 419 p. 	181). The regurgitation volumes observed in vitro at low 
heart rates could be significant at low cardiac outputs. One of the 
reasons for this result could be the asynchronous closing of the 
leaflets. The asynchronous closing of the leaflets is in our opinion an 
inherent problem with any bileaflet design, since you can not make both 
leaflets identical. The central flow field created by the valve is an 
advantage. The wall shears could cause sub-lethal damage to the 
endothelial lining of the vessel walls especially in the aortic 
position, while the turbulent shear stresses could cause sub-lethal 
and/or lethal damage to blood elements. It is therefore not surprising 
to observe mild hemolysis and TEC events, with this prosthesis. The 
region of flow separation could cause excess tissue growth on the 
downstream sewing ring which in turn could lead to valve dysfunction by 
impeding movement of the leaflets. This situation could be aggravated 
by certain surgical techniques such as using pledgets to sew the valve 
into place. It is therefore of utmost importance that the physician be 
able to monitor the movement of the leaflets under cinefluoroscopy. One 
of the major clinical disadvantages of the St. Jude valve is its poor 
radiographic visibility, especially if the physician is not familiar 
with the prosthesis. The problem of leaflets sticking has not been 
documented in the medical literature, but our observations in the pulse 
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1 3. 
HALL-CASTER TILTING DISC VALVE 
(a)Valve Description 
The Hall-Kaster valve is composed of a tilting disc of pyrolytic 
carbon within a titanium housing. The housing is machined from a single 
piece of solid titanium, eliminating the need for welds. The disc 
pivots to an angle of 75 degrees in the aortic model, and 70 degrees in 
the mitral model, in the fully open position. The disc is marked by a 
radio-opaque marker. The sewing ring is made of knitted Teflon. The 
valve has been in clinical trials since 1978 and was recently approved 
for general clinical use by the FDA. 
Sizes and Dimensions 






21 21 16 2.01 
23 23 18 2.54 
25 25 20 3.14 
27 27 22 3.80 
29 29 24 4.52 
31 31 24 4.52 
(b)In Vivo Results 
The Hall-Kaster tilting disc prosthesis has like the St. 	Jude 
valve been in clinical evaluations since 1978. It was recently approved 
by the FDA for general clinical use (December 1981). Approximately five 
thousand of these devices have been implanted world wide and a majority 
of them in Europe. In vivo clinical data indicate good 
	














IN VIVO PRESSURE DROPS: HALL-KASTER MITRAL VALVE  
Rest 











mmHg 	mmHg re fl/ 
27 	 3 	 6.0+4.4** 	NA 	3.03+0.58** 
3 	 6.0 	 4.9 	 3.08 
(4.1-5.6) 
29 	 3 	 4.7 	 NA 	 3.18 	3 
2 	 NA 	 NA 	2.86+1.46** 
8 	 2.1 	 NA 	 3.44 	8 













** + SD 
• 
Ref # (Irms 
L/min 
VA 	 RV 
2 3 
cm 	 cm /stroke 
Tissue Annulus 	Model 	Al"--; 	 CO 
Diameter 	 # mmHg R./min 
mm 
TABLE 73 
IN VITRO PRESSURE DROPS: HALL-KASTER AORTIC VALVE 
21 AHK 13.5 1, 5.3 20 1.76 5.4 425 
25 AHK 5.25 % 5.3 20 2.82 7.8 425 
27 AHK 6.5 % 7.5 30 .3.80 9.0 425 
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500 dynes/cm 2 and maximum turbulent shear stresses (estimated from 
turbulence intensity measurements) to be on the order of 500 to 1500 
dynes/cm 2 . A region of flow separation was observed in the minor 
outflow region adjacent to the sewing ring and flow channel walls. In 
addition, small regions of stagnation existed immediately downstream 
from the two metal pivot stops in the major orifice, and along the pivot 
post of the minor orifice. 
(d) Correlation 
In vivo and in vitro pressure measurements indicate that the 
Hall-Kaster valve has improved pressure drop characteristic compared to 
the Lillehei-Kaster and Bjork-Shiley tilting disc valves. At low heart 
rates and low cardiac outputs (for example, immediately after open heart 
surgery) the regurgitant volume across this valve design could be 
significant. 
The wall shears created by the valve could cause sublethal damage 
to the endothelial lining of vessel walls especially in the aortic 
position. The measured in vitro turbulent shear stresses could lead to 
sublethal and/or lethal damage to red cells and platelets. Therefore it 
is not surprising that mild to moderate hemolysis and thromboembolic 
problems are clinically observed with this prosthesis. Other possible 
reasons for the hgh LDH levels measured in patients (indication of 
hemolysis) with this valve design are: (a) the large amount of exposed 
metal on the prosthesis superstructure, and (b) leakage through the 
central pivot hole when the valve is closed. If most of the leakage 
volume occurs through this central pivot hole, the shear stresses 
TABLE 76 
THROMBOEMBOLIC COMPLICATIONS ; 	 HALL-KASTER TILTING DISC VALVE 
Position Modell/ Patient 
Ratio 
Rate 
% per pt-yr 
Deaths 
A AHK 7/233 2.3 1 
A AHK 1/113 NA 0 
M MHK 0/22 0 0 
ri MHK 8/112 7.8 2 
double AHK fi 2/57 3.4 0 
MHK 
Anticoagulation 	Remarks 	 Ref 0 
all patients 	 400 
all patients 	 401 
all patients 	 402 
all patients 	 400 
all patients 	 400 
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III. CONCLUSIONS 
Following the collection, analysis, and interpretation of the in 
vivo and in vitro information and data pertaining to the current state 
of the art in respect to the safety and performance of prosthetic heart 
valves (mechanical and tissue), Georgia Tech concludes that: 
(1)At present we do not have an ideal prosthetic heart valve. 
During the past 20 years manufacturers have developed and produced 
various designs of prosthetic heart valves, some of which perform 
satisfactorily when implanted surgically in patients suffering from 
valvular heart disease. Other designs have had to be removed from the 
open marked due to lack of adequate safety and efficacy. 
(2)There is a lack in vivo clinical and in vitro fluid dynamic 
data and information on all designs of prosthetic heart valves in 
current clinical use. The lack of good quality clinical information and 
data on some of the older valve types is surprising. 
(3)Good long term clinical follow up data exists only for the 
following valve types studied: (i) Starr-Edwards ball valves, (ii) 
Rjork-Shiley tilting disc valve, (iii) Lillehei-Kaster tilting disc 
valve, and (iv) Hancock porcine valve. 
(4)There is a lack of good detailed pathologic studies performed 
on heart valve prostheses recovered at surgery and/or autopsy. The lack 
of such studies will hinder the progress and development of not only 
better heart valve prostheses, but also other future artificial devices 
such as left ventricular assist devices and the total artificial heart. 
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(9)All prosthetic valves (mechanical and tissue) in current 
clinical use cause sublethal and/or lethal damage to blood elements such 
as red cells and platelets. The shear fields created by the valves are 
all capable of causing such damage. Sublethal damage to red cells could 
in time lead to mild hemolysis. 	Similarly, sublethal damage to 
platelets could over a period of time lead to thromboemboli and 
thromboembolic complications. 
(10) All peripheral flow type valves cause damage to the 
endothelial lining of the proximal ascending aorta. This is directly 
related to the elevated wall shear stresses in the immediate downstream 
vicinity of these valves. They may also cause sublethal and/or lethal 
damage to the ventricular wall. Other mechanical designs and tissue 
bioprostheses could cause sublethal and/or lethal damage to the 
endothelial lining of the aortic wall. The jet type flow from the 
tissue valves could cause damage to the ventricular wall. Depending on 
the orientation of the valve the flow in the major orifice region of the 
tilting disc valve could also cause damage to the ventricular wall. 
Depending on the orientation of the valve the flow in the major orifice 
region of the tilting disc valve could also cause damage to the 
ventricular wall. 
(11)All prosthetic valves in current clinical use cause hemolysis 
and thromboembolic complications, and are prone to the problems of 
thrombus formation and excess tissue growth on the valve superstructure. 
(12)In many cases the hemolysis caused by the prosthesis is mild 
or moderate, and is generally compensated for quite adequately by the 
bone-marrow. Cloth covering on the valve superstructure (such as with 
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IV. RECOMMENDATIONS 
1. Set up a national registry for prosthetic heart valves 
immediately. 	Detailed pathologic, and non-destructive and destructive 
engineering studies should be conducted on recovered valves, under the 
auspicies of the registry. At the time of valve implantation surgery, 
patients should be requested to sign a release so that the valve or 
valves may be recovered for scientific purposes at death. Current 
implant retrieval programs conducted by some of the manufacturers do not 
facilitate free transfer of information between medical and scientific 
communities. It seems as if those valve prostheses disappear from the 
public domain. 
2. An educational program should be estimated for patients which 
provides reliable and accurate scientific information regarding the 
current status of various heart valve prostheses, their uses and 
limitations, and potential problems. 
3. Require good clinical follow up data on all designs of valve 
prostheses. 	Such clinical follow up should include more detailed and 
sensitive tests to study blood component damage. For example, half-life 
studies should be conducted on tagged red cells and platelets. The 
filter ability of the red cells in micropores should also be studied. 
It may be necessary in the initial stages to sponsor such studies at a 
few major medical centers. 
4. Standardized methodology should be established for reporting 
hemodynamic, hemolysis and TEC data. Such an effort would require the 
cooperation of the American Heart Association, American College of 
191 
community should appreciate the value of in vitro testing and the 
problems associated with such testing studies. On the other hand, the 
engineer should understand the problems faced by the cardiovascular 
surgeon and cardiologist. The collaboration and communication should 
take place in both directions. 
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SUMMARY 
The following report is a detailed experimental study of 
the in vitro fluid dynamic characteristics of different designs 
of prosthetic heart valves in current clinical use. The study 
was conducted under Food and Drug Administration contract 
# 223-81-5000, which lasted approximately two years. It should, 
however, be noted that due to the limitations of time and money 
not all the questions regarding the fluid dynamic performance of a 
given valve design could be answered. Since it is anticipated 
that the report will be read by scientists, engineers and physicians, 
the report has been written in three parts. 
Part I summarizes the in vitro fluid dynamic characteristics 
of each valve design (ie: the experimental results), and attempts 
to relate these results to possible clinical and pathologic 
problems. No comparisons are, however, made between the different 
valve designs. Part II contains the details of the experimental 
equipment and techniques used during the study. Part III contains 
the detailed experimental data in graphical, tabular and/or 
photographic forms. All the chapters, pages, figures, and tables 
are consecutively numbered in numerical order. 
For the reader who is only interested in the overall results 
of the study, reading Part I of the report would be sufficient. 
Parts I and III of the report will be on microfilm with NTIS. 
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CHAPTER I 
INTRODUCTION AND BACKGROUND  
The major objective of this project was to investigate the in vitro  
fluid dynamic characteristics of different designs of prosthetic heart 
valves, in both aortic and mitral flow chambers. The valves that were 
studied are listed below in Table 1, together with their sewing ring and 
primary orifice diameters. 
In some instances the experimental methodology and techniques 
were changed from the original contract, based upon the findings of 
preliminary experiments. The philosophy that governed these changes was 
aimed at providing the FDA with the best possible scientific and engineering 
information, within the budget and time constraints of the project. Changes 
made during the contract are noted in the appropriate places within the 
text. 
TABLE 1: PROSTHETIC HEART VALVES USED IN STUDY 
Name of Valve 	 Sewing Ring Diameter 
mm 




Starr-Edwards 1260 27 17.0 
Starr-Edwards 6120 28 18.0 
Smeloff 26 17.1 
Beall 28 16.5 
Bjork-Shiley (C-C) 27 22.0 
*Medtronic-Hall (AHK) 27 22.0 
*Medtronic-Hall (MHK) 27 22.0 
St. Jude 27 22.3 
Hancock (Std) 27 22.5 
Hancock (MO) 25 21.8 
Carpentier-Edwards 27 23.0 
Ionescu-Shiley 27 23.4 
*Formerly known as the Hall-Kaster valve 
Heart valve prostheses have been used successfully since 1960. As 
stated by Roberts (1) the decade of 1960 will probably be remembered 
most in the annals of cardiology as the decade during which cardiac 
valve replacement became a successful reality. Of the nearly 50 different 
cardiac valves introduced over the past 20 years, many have been discarded 
due to their lack of success, and of those remaining, several modifica-
tions have been made or are being made at the time of this writing. The 
most commonly used basic types of prosthetic valves at present are 
(a) caged ball, (b) tilting disc, (c) caged disc, (d) bi-leaflet and 
(e) bioprosthesis. At present over 75,000 prosthetic valves of different 
designs are used annually throughout the world. Even after 20 years of 
experience the problems associated with heart valve prostheses have not been 
totally eliminated. The most serious problems and complications associated 
with heart valve prostheses are: (a) throMboembolism, (b) tissue over-
growth, (c) infection, (d) tearing of sewing sutures, (e) red cell destruc-
tion (hemolysis), (f) valve failure due to material fatigue or chemical 
change, (g) damage to the endothelial tissue lining of the vessel wall 
adjacent to the valve and (h) leaks caused by failure of the valve to close 
properly. Problems (a), (b), (e) and (g) are directly related to the fluid 
dynamics associated with the various prosthetic heart valves, and need to 
be addressed in more detail by investigators studying bio-fluid mechanics. 
The other problems are indirectly related to the fluid mechanics. The 
problems relating valve failure due to material fatigue or chemical change 
also need to be studied especially as they relate to bioprostheses. 
Tissue bioprostheses gained wide spread use during the mid-1970's. 
It was even naively thought by some of the tissue valve manufacturers 
that the ideal heart valve prosthesis had been discovered. The major 
advantage of tissue bioprostheses compared to their mechanical counter- 
parts is that they appear to have a lower incidence of thromboembolic c 	mplications. 
Therefore, tissue valves for a large part can be used without anticoagul- 
ation therapy to eliminate or reduce thromboembolic complications. 
Unfortunately, the tissue bioprostheses clinically used at present also 
have major disadvantages such as: (a) relatively large pressure drops 
compared to some of the mechanical valves, especially in the smaller sizes, 
(b) jet-like flow through the valve leaflets, (c) calcification, material 
fatigue and/or wear of valve leaflets, especially in children. Because of 
these and other drawbacks valve manufacturers are now developing new 
designs of mechanical valves such as the St. Jude, Medtronic-Hall and Omni-
Science prostheses, newer designs of bioprostheses and trileaflet valves 
made from polymeric materials. 
The ideal heart valve prosthesis has not yet been designed and 
probably will neven exist. An ideal valve should have the following 
characteristics: 
1. Be fully sterile at the time of implantation and be nontoxic. 
2. Be surgically convenient to insert at or near the normal location 
in the heart. 
3. Conform to the heart structure rather than the heart structure 
conform to the valve (i.e., the size and shape of the prosthesis 
should not interfere with cardiac function). 
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4. Show a minimum resistance to flow so as to prevent a significant 
pressure drop across the valve. 
5. Have minimal reverse flow necessary for valve closure, so as 
to keep the incompetence of the valve at a low level. 
6. Show low mechanical and structural wear of the valve. 
7. Be long-lasting ( - 25 years), and maintain its normal functional 
performance (i.e. must not deteriorate with time). 
8. Cause minimum trauma to blood elements and the endothelial tissue 
of the cardiovascular structure surrounding the valve. 
9. Show a low probability for thromboembolic complications without 
the use of anticoagulants. 
10. Should not be noisy and disturb the patient. 
11. Should be radiographically visible. 
12. Should have a modest price. 
As stated previously the serious problems of thromboembolism, excess 
tissue overgrowth, red-cell and platelet damage, and damage to the 
endothelial lining of the vessel wall adjacent to the valve are directly 
related to the fluid dynamics associated with the various types of valve 
prostheses. Blackshear and his co-workers (2,3) suggest that the shear 
stresses required in the bulk of the flow to hemolyze red blood cells 
are about 40,000 dynes/cm2 . Nevaril and his co-workers (4) contend, 
however, that this value could be as low as 1500 dynes/cm
2 . In vitro 
experiments (5-7) have also recently shown that platelets could be 
damaged by shear stresses of the order of 100-500 dynes/cm2 . A formed 
element such as a red blood cell which adheres to the vessel wall or to 
a foreign surface (such as the valve superstructure) may be damaged by 
6 
shear stresses of the order of 10-10 2 dynes/cm2 (2, 3, 8). Lloyd, et al., 
(9) indicate that sublethal damage to red blood cells could occur at shear 
stresses on the order of 500 dynes/cm 2 or less. A recent study by 
McIntyre indicates that the red blood cells of heart valve patients are 
more filterable in micropores than compared to normal subjects, due to 
sublethal damage to the red cells of valve recipients. Lethal damage to 
red blood cells causes hemolysis which in turn leads to anemia. Sublethal 
and/or lethal damage to red blood cells could also lead to platelet 
adhesion, aggregation and coagulation, resulting in thrombus formation. 
Mechanical damage to platelets (lethal and sublethal) will eventually 
lead to thromboembolic complications. 
Fry (10, 11) has conducted two studies on the effects of wall shear 
on the endonthelial lining of the aortic wall. He found that the 
endothelial cells on the vessel wall could be damaged at wall-shear 
stresses of about 400 dynes/cm2 and could be eroded off the vessel wall 
at shear stresses of about 950 dynes/cm 2 . He observed that when the 
endothelial surface was exposed to shearing stresses above some critical 
value (400 dynes/cm2) the cells began to suffer structural and chemical 
changes. The critical stress is known as the "yielding" stress. If a 
shearing stress above the critical value is applied for a long time 
period, the yielding process continues until the cells become mechanically 
unstable and are washed away from their moorings to the basement membrane 
in total or by progressive erosion of cell substance. As the eroded 
surface of the vessel wall is exposed to the flowing blood, deposition 
of blood elements and thrombotic materials occur. Fry found that the 
deposited material consisted of fibrous tissue, platelets, red blood cells, 
and other unidentified debris. He states that such deposition could lead 
to intimal thickening of the vessel wall. Woolf and Carstairs (12) state 
that the fibrous tissue observed on the aortic wall as a result of 
intimal thickening owes its pressence to either infiltration or thrombus 
formation, or a combination of these two factors. 
Platelets do not adhere to intact endothelial cells but they do 
adhere to subendothelial connective tissue composed of collagen and 
other materials. Platelets, however, have access to collagen fibers 
once the endothelial lining of a vessel wall is damaged or eroded off. 
The adhesion of platelets to the damaged vessel leads to the subsequent 
release of ADP and platelet factor 3 (PF-3). These substances play an 
active role in platelet aggregation and coagulation, respectively, and 
may lead to thrombus formation. A red blood cell will not stick to the 
intact endothelial lining of a vessel wall. If, however, the vessel 
intima is damaged resulting in a loss of endothelial integrity, red blood 
cells could adhere onto the vessel wall. If the adhered red blood cell is 
exposed to shears on the order of 10 to 100 dynes/an 2 it will probably be 
lethally damaged and hemolyzed. Red blood cells contain ADP and a clot-
promoting factor known as erythrocin. These substances are released into 
the plasma as a result of rbc hemolysis initiating both platelet 
aggregation and coagulation, which in turn may lead to thrombus formation. 
The mechanical damage to the blood elements, as well as to the 
endothelial tissue of the adjacent vessel wall, may in addition trigger 
the compelx biochemical reactions which could lead to the excess fibrous 
tissue overgrowth observed on some recovered heart valves. Therefore, 
large wall and bulk turbulent shear stresses could cause serious problems 
and complications in vivo. 
It is also well known that regions of flow stagnation, flow separation 
and excessively low shear in the immediate vicinity of the valve super-
structure have been related to thrombus formation and/or excess tissue 
overgrowth on the prosthesis. The flow velocity, shear stress and pressure 
fields in the immediate vicinity of a given heart valve prosthesis design 
are directly related to the fluid dynamic characteristics of the prosthesis. 
Therefore, detailed in vitro fluid dynamic studies should help predict 
potential problems and complications that may arise in vivo, with different 
designs of prosthetic heart valves. 
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CHAPTER 2 
SUMMARY OF IMPORTANT RESULTS 
I. VALVES IN THE AORTIC POSITION 
(i) Starr—Edwards Model 1260 Ball Valve 
The Starr—Edwards ball has poor pressure 	drop 
characteristics as indicated by a performance index (PI) 
of 0.30. The valve will be "pry stenotic under excercise 
conditions. The closure bPck flow (@ 70 beats/min) was 
5.5 cm3 /beat, while the leakage back flow was 
negiligible. 
The forward flow emerging form this valve forms an 
axisymmetric circumferential jet. The velocity of the jet 
reaches a value of 180 cm/s at peak systole. The 
turbulent shear stress could be as large as 3000 dynes/cm 2 
in the annular region between the ball and the flow 
channel wall. Such high shear stresses could cause 
sub—lethal and/or lethal damge to blood elements. 
The circumferential jet separates from the surface of 
the ball at a 45 degree angle to the axial direction and 
impinges on the wall of the flow channel. The highest 
estimated wall shear stress is 1940 dynes/cm 2 , which is 
large enough to damage the endothelial lining of the 
aorta. A large wake exists distal to the ball and extends 
1 0 
about 50 mm downstream from the valve sewing ring. The 
region immediately downstream of the cage apex is 
relatively stagnant and is a probable site for thrombus 
formation. 
An annular region of flow separation can be observed 
adjacent to the valve sewing ring, up stream of the 
circumferential jet. ThP low flow in this region makes 
the downstream sewing ring region, especially at the 
struts, vulnerable to thrombus formation and/or excess 
tissue growth. The measurements upstream of the valve 
during diastole show that the leakage back flow for this 
valve design is negligible. 
(ii) Bjork-Shiley Convexo-Concave Tilting Disc Valve  
The Bjork-Shiley valve had a PI of 0.45, which 
indicates that it could be stenotic under moderate to 
severe excercise conditions. The closing and leakage back 
flows were measured to be 4.5 cm3 /beat and 4.0 cm 3 /beat 
, respectively. At low cardiac outputs (0 1/min) the 
regurgitant volumes measured with this valve could become 
clinically significant. 
The valve produces an uneven flow field, with the 
forward flow primarily going through the major orifice. 
The flow emerging form the major orifice is jet-like 
throughout the major portion of systole. The jet impinges 
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on the flow channel wall with high velocity and generates 
a wall shear stress of 1380 dynes/cm 2 . This high wall 
shear atress could cause damage to the endothelial lining 
of the aortic wall. A small region of flow separation 
exists adjacent to the major orifice sewing ring, between 
the major orifice jet and the flow channel wall. The 
velocity of the major orifice jet is about 210 cm/s at 
peak systole, with turbulent shear stresses on the order 
of 1800 dynes/cm2 The flow region underneath the disc 
appears to be relatively stagnant throughout the systole. 
This region never gets "washed", which could lead to 
thrombus formation on the aortic face of the disc. 
The flow field in the minor orifice region is much 
more disturbed than that in the major orifice region. The 
peak velocity of the minor orifice jet is about 210 cm/s. 
A large region of flow separation exists between the minor 
orifice jet and the flow channel wall. The low flow 
velocities adjacent to the sewing ring in the minor 
orifice region, could lead to tissue overgrowth along the 
sewing ring in this region. The obstruction of the valve 
occluder generates a shear stress as high as 3300 
dynes/cm2 just underneath the occluder. This high shear 
stress could cause sublethal and/or lethal damage to blood 
cells. Leakage back flow occurs adjacent to the flow 
channel wall, directly upstream of the annular gap between 
the occluder and the valve orifice ring, with a negative 
.LL 
velocity as high as -22 cm/s, and turbulent shear stresses 
on the order of 430 dynes/cm
2 
. 
(iii) Medtronic-Hall Tilting Disc Valve 
The Medtronic -Hall tilting disc valve has good 
pressure drop characteristics (PI = 0.64). The 
regurgitation characteristics of this valve design could 
become clinically significant at low cardiac outputs 
(closure back flow 5.1 cm 3 /beat ; leakage back flow 4.3 
cm3 /beat ). 
The flow field produced by this valve design is also 
asymmertric, with the forward flow primarily occuring 
through the major orifice. High velocity jet-like flow 
can be seen from either orifice at peak systole. The 
highest velocities of these two jets are about the same 
magnitude (210 cm/s). High shear stresses are more spread 
out in the minor orifice than in the major orifice, which 
indicates that the flow in the minor orifice region is far 
more disturbed. A 12rge region of flow separation exists 
in the minor orifice region adjacent to the sewing ring. 
The comparatively low fluid velocities in this region 
makes the downstream sewing ring in the minor orifice a 
vulnerable site for tissue overgrowth and/or thrombus 
formation. The metal strut superstructure in the major 
orifice appears to have only a small effect on the shear 
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stress field in the major orifice. In the minor orifice, 
a wake exists downstream of the strut and reduces the 
velocity sharply, which makes this strut structure a 
possible location for thombus formation. The highest 
shear stress observed over the entire systolic period 
occurred at the edge of the major and the minor orifice 
jets and was on the order of 2000 dynes/cm 2 . Such high 
shear stresses could lead to blood cell damage, especially 
in the minor orifice region where the shear stresses are 
elevated over the entire systolic period. 	The highest 
estimated wall shear stress was 700 dynes/cm 2 , and was 
measured at the location where the major orifice jet 
impinged on the flow channel wall. This high wall shear 
stress could cause sublethal damage to the endothelial 
lining of the aortic wall. 
Back flow during diastole occurred as a very narrow 
intense jet through the central pivot hole , with a 
velocity of —30 cm/s and shear stresses as high as 680 
dynes/cm2 . Such shear stresses could cause blood cell 
damage. 
(iv) St. Jude Bileaflet Valve 
The St. 	Jude valve has the best pressure drop 
characteristics, 	PI r. 0.71, of all the designs of 
prosthetic heart valves in current clinical use. 	The 
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regurgitation characteristics of this valve could create 
clinical problems at low cardiac outputs. The valve has a 
closure back flow of 5.5 cm 3 /beat , and a leakage back 
flow of 5. 1 cm3 /beat . 
Flow through this valve forms three jet-like flow 
fields, two from the two side orifices and one from the 
center orifice. The flow emerging from the center orifice 
is more disturbed then that emerging from the side 
orifices. The jets from the side orifices are wider than 
that from the center orifice. This suggests that the 
major part of the volumetric flow tends to go through the 
side orifices. Regions of flow separation can be observed 
adjacent to the downstream sewing ring. The largest 
regions of flow separation occurs at either end of the 
center orifice (ie: near the pivot points), and would be 
the most likely locations for tissue overgrowth and/or 
thrombus formation to occur. Since the hinges of the 
valve leaflets are in these regions and leaflet motion is 
susceptible to easy interference, prosthetic valve 
dysfunction could occur. 
The two leaflets of the St. Jude valve do obstruct 
the flow and reduce the fluid velocity distal to the 
leaflets, and also create high turbulent shear stresses. 
The highest turbulent shear stress measured was on the 
order of 2000 dynes/cm2 . The measurement was made in the 
side orifice close to the valve leaflet at peak systole. 
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The highest turbulent shear 	stresses during the 
accelaration and decelaration phases are 1630 dynes/cm 2 
 and 1370 dynes/cm2 ,respectively. These high shear 
stresses could lead to sublethal and/or lethal blood cell 
damage. Wall shear atresses with this valve design are 
generally low ( -630 dynes/cm2 ), but still can cause 
sublethal damage to the endothelial lining of the aortic 
wall. Leakage back flow occurs upstream of the central 
pivot of the valve during diastole, with a velocity as 
high as -16 cm/s and turbulent shear stresses on the order 
of 325 dynes/cm2 . 
(v) Carpentier-Edwards Bioprosthesis  
This valve is without a doubt stenotic (PI = 0.34), 
and will be very stenotic under excercise conditions. The 
valve has a very small closing back flow (0.9 cm 3 /beat ) 
and no measureable leakage during diastole. The leaflet 
motion characteristics of the Carpentier valve leave much 
to be desired. The valve leaflets only opened to 70% of 
the stent orifice area at a cardiac output of 7.5 1/min. 
This valve produces a very high velocity jet-like 
flow, which emerges from the triangular opening of the 
valve leaflets. The jet does not dissipate until 65 mm 
downstream from the valve sewing ring. The velocity of 
the jet at peak systole is as high as 360 cm/s. Very high 
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turbulent shear stress exists in the narrow region around 
the edge of the jet, with values as high as 4400 dynes/cm 2 
. Although this high shear stress only occurs at peak 
flow, sublethal and/or lethal damage to blood elements is 
very likely to occur. 
The flow separates from the downstream edge of the 
leaflets. Regions of flow separation exist around the jet 
and extend as far downstream as 75 mm from the sewing 
ring, during deceleration phase. The annular region 
between the outflow surfaces of the leaflets and the flow 
channel wall is stagnant, which could lead to the 
deposition of thrombotic, fibrotic and/or calcific 
material on the outflow surfaces of the leaflets. The 
region of flow separation adjacent to the downstream 
sewing ring could lead to the build up of excess fibrotic 
tissue. The highest estimated wall shear stress with this 
valve was 460 eynes/cm2 , which could cause sublethal 
damage to the endothelial lining of the vessel wall 
adjacent to the valve. There was no measurable leakage 
for this valve design. 
(vi) Hancock Modified Orifice Procine Xenograft  
Of the three procine valves studied in this project 
the Hancock modified orifice valve was the least stenotic 
(PI = 0.39). However, the pressure drop characteristics 
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indicate that the valve will become stenotic under 
moderate excercise conditions. The closing back flow for 
this valve was 0.8 cm3 /beat . The valve leaflets opened 
to 80% of the stent orifice area (@ cardiac output of 7.5 
1/min). 
The valve produces a high velocity central jet which 
does npt dissipate until 80 mm downstream from the valve 
sewing ring. The highest velocity measured was 330 cm/s. 
The high turbulent shear stresses (3000 dynes/cm 2 ) 
produced by this valve in the jet could lead to sublethal 
and/or lethal blood cell damage. However, this high 
turbulent region is confined to a narrow region around the 
jet. Flow separates from the downstream edge of the valve 
leaflets. A region of flow separation exists around the 
jet and extends 65 mm downstream of the sewing ring at 
peak systole. The annular region between the outflow 
surfaces of the leaflets and the flow channel wall is 
relatively stagnant. This region could lead to the 
deposition of thrombotic,fibrotic and/or calcific material 
on the outflow surfaces of the leaflets. The region of 
flow separation adjacent to the downstream sewing ring 
could lead to the build up of excess fibrotic tissue. The 
highest estimated wall shear stress was 490 dynes/cm 2 , 
which could cause sublethal damage to the endothelial 
lining of the aortic wall. The leakage back flow for this 
valve design is also negligible. 
• 
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(vii) Ionescu-Shiley Pericardial Xenograft  
The 	Ionescu-Shiley valve had 	pressure 	drop 
characteristics similar to that of the Hancock (MO) valve 
studied (PI = 0.41). The closure backflow for this valve 
design, 5.2 cm 3  /beat , was larger than that measured wuth 
the three porcine valves studied. This valve had the best 
leaflet opening and closing characteristics (opening area 
was 95% of stent orifice area) of the four tissue valves 
studied. 
This valve design, like the previous two tissue 
valves, also produces a jet-like flow field. The jet is 
not axisymmertric, but skews towards the bottom of the 
flow channel. This is something that was not expected by 
examining the valve, since the valve appears to have a 
symmetric geometry. The skewness of the jet is probably 
due to the differeces in elestic characteristics of the 
three valve leaflets. The velocity of the jet has a 
maximum value of 231 cm/s at peak systole. The jet has a 
very steep velocity gradient which causes a drastic change 
in turbulent shear stress in the region around the jet. 
The turbulent shear stress could be as high as 2500 
dynes/cm , which could lead to sublethal and/or lethal 
blood element damage. 
Flow separates from the downstream edge of the 
leaflets. 	Regions of flow separation are visible around 
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the jet and extend as far downstream as 80 cm from the 
valve sewing ring. The annular region between the outflow 
surfaces of the leaflets and the wall of the flow channel 
is stagnant. However, due to the convex shape of the 
leaflets, the region of stagnation is small, which should 
tend to reduce the possibility of calcific and thrombotic 
deposits, and tissue overgrowth. The highest estimated 
wall shear stress was about 400 dynes/cm 2 for this valve. 
The velocity profile upstream of the valve 20 ms after the 
end of systole, indicates a large amount of fluid is 
displaced by the closing movement of the valve leaflets, 
which creates negative velocities on the order of —35 
cm/s. 
(viii) Smeloff Caged Ball Valve' 
The pressure drop characteristics of the Smeloff 
valve are better than the Starr—Edwards ball valve, but 
are still less than desirable. The Smeloff valve has a PI 
of 0.36. The regurgitation characteristics are quite 
baffling because of the excessive leakage flow that was 
measured (closing backflow 4.5 cm 3 /beat ; leakage 
backflow 11.6 cm3 /beat ) 
' Velocity measurements were not conducted with this 
valve. 
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This valve produces a circumferential jet—like flow 
field. The jet separates from the ball about 1/8th the 
way around it, with a 60 degree angle to the axial 
direction. A large turbulent wake can be observed distal 
to the ball throughout systole. This area of turbulence 
is caused by the vortices which are shed from the distal 
surface of the ball, as a result of boundary layer 
separation. The wake extends about 60 mm downstream of 
the sewing ring at peak systole. 
The velocity of the fluid in the annular region 
between the ball and the flow channel wall appears to be 
very high and jet like. Since the poppet creates a lot of 
obstruction to the flow, the turbulent shear stresses 
produced by this valve design are also expected to be very 
high and quantitatively similar to those measured with the 
Starr—Edwards ball valve. 
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II . VALVES IN THE MITRAL POSITION 
(1) Beall Caged—Disc Valve  
The Beall caged disc valve was the most stenotic 
valve studied, with a performance index (PI) of 0.19. The 
valve is very stenotic even at a normal resting cardiac 
output. The valve had a closing back flow volume of 3.0 
cm 3 /beat (@ 70 beats/min), and no measurable leakage 
volume during systole. 
A very thin circumferential jet emerges around the 
valve occluder at peak systole with high velocity. The 
highest velocity measured was 113 cm/s. Flow separates 
from the edge of the occluder, which forms a large 
doughnut shaped vortex distal to the valve. Reverse flow 
occurs in the central part of the flow channel. A region 
of stagnation exists in the center of the flow field 
immediately adjacent to the downstream face of the 
occluder. Such a region of stagnation could lead to 
thrombus formation on the downstream face of the disc and 
the struts. This could lead to improper disc motion, and 
also increased disc wear. An annular region of flow 
separation exists adjacent to the downstream sewing ring, 
which could cause tissue overgrowth and/or thrombus 
formation around the sewing ring and the base of the 
struts. 
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This valve produces turbulent shear stress as high as 
1900 dynes/cm2 around the edge of the occluder, which 
could cause sublethal and/or lethal damage to blood 
elements. However, the high shear stress is confined to a 
thin region around the jet at peak flow, which decays very 
quickly as the flow travels downstream. The highest 
estimated wall shear stress for this valve design was 1780 
dynes/cm2 . Such wall shear stresses could damage the 
endothelial lining of the ventricular wall adjacent to the 
valve. 	The leakage back flow for this valve design is 
negligible. 
(ii) Bjork-Shiley Convexo—Concave Tilting Disc Valve  
In the mitral position the Bjork-Shiley valve had a 
PI of 0.38, which indicates that this valve design could 
be stenotic under severe exercise conditions. The closing 
back flow and leakage back flow volumes were 4.3 and 2.1 
cm3 /beat ,respectively. 
The valve produces two jet type flow fields, one from 
the major orifice and the other from the minor orifice. 
The major orifice jet is wider than the minor orifice jet. 
Forward flow occurs mainly from the major orifice. The 
highest turbulent shear stress was measured in the major 
orifice jet and was on the order of 500 dynes/cm 2 . Such 
turbulent shear stresses could cause sublethal damage to 
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the blood elements. A small region upstream of the major 
orifice jet and adjacent to the downstream sewing ring, 
appears to be stagnant throughout entire diastole. This 
could lead to tissue overgrowth and/or thrombus formation 
along this region of the major orifice sewing ring. A 
large region of flow separation exists between the minor 
orifice jet and the flow channel wall. The region 
adjacent to the sewing ring in the minor orifice region is 
relatively stagnant, which makes it a possible site for 
tissue overgrowth. The region beneath the valve occluder 
in the minor orifice region is stagnant throughout the 
distole, which could lead to the deposition of thrombotic 
material on the outflow face of the disc. 
The highest estimated wall shear stress was 620 
dynes/cm2 , and occurred approximately where the major 
orifice jet hit the wall of the flow channel. This 
magnitude of wall shear stress could cause sublethal 
damage to the endothelial lining of the ventricular wall. 
Small amounts of back flow exist adjacent to the flow 
channel wall, upstream of the valve. The highest 
turbulent shear stress caused by the leakage back flow was 
80 dynes/cm2 . 
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(iii) Medtronic-Hall Tilting Disc Valve 
The Medtronic-Hall valve had relatively good pressure 
drop characteristics with a PI of 0.43. The closing and 
leakage back flow volumes were 4.7 and 2.4 cm 3 /beat , 
respectively. The regurgitation characteristics of this 
valve design could become clinically dignificant at low 
cardiac outputs (<3 1/min). 
Most of the forward flow emerging from this valve is 
through the major orifice. The highest velocities are 105 
cm/s and 97 cm/s in the major and the minor orifices, 
respectively. Turbulent shear stress as high as 2500 
dynes/cm2 were measured in the major orifice region 
immediately downstream of the strut superstructure. The 
highest turbulent shear stress measured in the minor 
orifice region was 1800 dynes/cm 2 . The occluder of the 
Medtronic-Hall mitral valve oscillates during diastole, 
which causes the flow field to be highly non-stationary. 
Such oscillations could lead to large fluctuations in the 
measured turbulent shear stresses, and cause an overall 
elevation of the turbulent shear field. The measured 
turbulent shear stress could cause sublethal and/or lethal 
damage to blood elements. 
A vortex structure exists adjacent to the sewing ring 
in the major orifice region, between the jet and the flow 
channel wall. This vortex is caused by boundary layer 
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separation from the valve orifice ring. A large region of 
flow separation can be observed in the minor orifice 
region adjacent to the sewing ring and the strut. This 
region of flow separation could lead to tissue overgrowth 
and/or thrombus formation along the sewing ring and the 
strut in the minor orifice region. The highest estimated 
wall shear stress with this valve. was 480 dynes/cm 2 , and 
occurred at the location where the major orifice jet hit 
the wall. Such wall shear stress could cause sublethal 
damage to the endothelial lining of the ventricular wall. 
During systole, back flow occurs through the central 
pivot hole like a jet, with a velocity as high as —17 cm/s 
and turbulent shear stress as large as 700 dynes/cm 2 . 
This elevated shear stress could lead to blood cell 
damage. 
(iv) St. Jude Bileaflet Valve 
In the mitral position as well, the St. 	Jude 
bileaflet valve has the best pressure drop characteristics 
(PI = 0.48) of all the valve designed studies. Its 
regurgitation characteristics (closure volume 5.0 cm3 
/beat ; leakage volume 2.5 cm3 /beat ) could, however, 
cause clinical problems at low cardiac outputs. 
The forward flow emerging form this valve is 
primarily through the two side orifices. At peak systole, 
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the valve produces three jet-like flow fields, two from 
the two side orifices and one form the center orifice. 
The peak velocities of the two side orifice jets are 
higher than that of the center orifice jet, with 
velocities as high as 103 cm/sec. The jets are centrally 
located in the flow channel, surrounded by an annular 
region of flow separation along the wall. The highest 
turbulent shear stress measured during diastole (760 
dynes/cm2 ) occurred in the center orifice flow field. 
This high shear stress occurs only at peak diastole and is 
confined to a narrow region. At this level of shear 
stress, blood cell damage may not be a serious problem. 
During our studies it had been observed that the two 
leaflets did not open synchronously, and the velocity 
measurements also confirmed this phenomenon, which is 
somewhat troubling. 
The region of flow separation observed adjacent to 
the downstream sewing ring, especially in the vicinity of 
pivot mechanism, could lead to tissue overgrowth and/or 
thrombus formation, and interfere with the motion of the 
valve leaflets. The highest estimated wall shear stress 
during diastole was 200 dynes/cm2 . During systole, back 
flow exists in the center part of the flow channel, with a 
reverse velocity as high as -17 cm/s, and a turbulent 
shear stress of 117 dynes/cm2 . 
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(v) Hancock Standard Porcine Xenograft  
The Hancock (Std) porcine valve is stenotic even at 
mild levels of excercise (PI = 0.26). The primary reason 
for this, is its poor leaflet motion characteristics. The 
valve leaflets opened to only 50% of the stent orifice 
area at a cardiac output of about 7.5 1/min. 
This valve produces a high velocity central jet. The 
velocity of the jet is has a maximum value of 216 cm/s at 
peak diastole. Flow separates from the downstream edge of 
the valve leaflets creating a region of flow separation 
around the jet and extends about 30 mm downstream of the 
sewing ring. The separation region is not very disturbed. 
The annular region adjacent to the sewing ring is stagnant 
throughout entire diastole. This region of stagnation 
could lead to tissue overgrowth around the sewing ring, 
and encourage calcific, thrombotic and/or fibrotic 
deposits on the outflow faces of the leaflets. 
The jet type flow creates high velocity gradients and 
also led to high turbulent shear stresses. The highest 
turbulent shear stress measured in the jet was 1947 
dynes/cm2 
	
Such high shear stress could lead to 
sublethal and/or lethal blood cell damage. 	The highest 
wall shear stress measured with this valve was 260 
dynes/cm2 . Leakage backflow with this valve design was 
negligible. 
(vi) Ionescu-Shiley Pericardial Xenograft  
In 	the mitral 	position the pressure 	drop 
characteristics of the Ionescu-Shiley were not impressive 
(PI = 0.32). At moderate levels of excercise the valve is 
stenotic. 	The valve leaflets opened to 79% of the stent 
orifice area at a cardiac output of 7.5 1/min. 	The 
closing back flow volume for this valve was 5.0 cm 3 /beat 
A high velocity jet-like flow also emerges from this 
valve, which occupied a narrow region in the central part 
of the flow channel. The highest velocity of the jet was 
190 cm/sec. 	High turbulent shear stresses, up to 1400 
dynes/cm2 , exist in a thin region around the jet. 	Flow 
separates from the downstream edge of the valve leaflets. 
The region between the outflow surfaces of the valve 
leaflets and the wall of the flow channel is stagnant 
throughout diastole. 
The high shear stresses created by this valve could 
lead to sublethal and/or lethal blood element damage. The 
region of stagnation around the valve leaflets could lead 
to tissue overgrowth around the sewing ring and encourage 
calcific, thrombotic and/or fibrotic deposits on the 
outflow surfaces of the leaflets. The highest estimated 
wall shear stress measured with this valve was 320 
dynes/cm2 . The measurements upstream of the valve during 
systole showed that the back flow occurred in the center 
of the flow channel, which was caused by the closing 
movement of the valve leaflets. 
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CHAPTER 3 
CONCLUSIONS AND RECCOMMENDATIONS 
I CONCLUSIONS 
Following the collection, analysis and interpretation 
of the in vitro fluid dynamic data, the following 
conclusion were made: 
(0 The pressure drops studies revealed that the new low 
profile mechanical valves, such as the St. Jude and 
Medtronic-Hall, had the best pressure drop 
characteristics. The procine valves in current 
clinical use (Hancock and Carpentier-Edwards) had 
poor pressure drop characteristics which need to be 
improved immediately . 
(ii) The low profile mecharical valves such as the 
Bjork-Shiley, St. Jude and Medtronic-hall prostheses 
have regurgitant volumes Winich could be clinically 
significant at low cardiac outputs. 
(iii)All the valve designs (mechanical and 	tissue) 
studied created turbulent shear stresses large 
enough which could cause sublethal and/or lethal 
damage to blood elements. With the mechanical 
valves, the elevated shear stresses were measured in 
the immediate vicinity of the valve superstructure. 
In the case of the tisslisl, valves, the elevated 
turbulent shear stresses occurred in the bulk of the 
fluid. 
(iv) Most of the valves studied in the aortic position 
created wall shear stresses which could cause 
subleathal and/or lethal damange to the endothelial 
lining of the aortic wall adjacent to the valve 
prosthesis. 
(v) All of the valve protheses that were investigated, 
created regions of flow separation and/or stagnation 
adjacent to their respective superstructures, which 
could lead to tissue overgrowth, and thrombotic 
and/or calcific deposits. 
(vi) The 	tissue 	valves 	studied 	(Hancock, 
Carpentier-Edwards and Ionescu-Shiley) have less 
than satisfactory leaflet motion characteristics. 
Of the tissue valves studied, the Ionescu-Shiley 
valve appeared to have the best in vitro fluid 
dynamic characteristics. 
(vii)From an in vitro fluid dynamic point of view, none 
of the valves in current clinical use even approach 
ideal status . The lack of attention paid to subtle 
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design parameters is the major reason for most of 
the flaws in the current valve designs. 
II RECOMMENDATIONS 
(i) Further detailed in vitro regurgitation studies 
should be conducted with different designs of 
prosthetic heart valves, to investigate the effects 
of heart rate and cardiac output on regurgitant (ie: 
closure and leakage) volumes. 
(ii) In vivo quantitative studies should also be 
conducted to evaluate the regurgitant characteristic 
of prosthetic heart valves. 
(iii)Detailed studies should be performed on the pressure 
drop characteristics and 	the leaflet motion 
characteristics of all new trileaflet valve designs. 
(iv) The pulsatile flow velocity measurments conducted in 
thes study should and must be expanded. Due to time 
and budget limitations experiments were only 
conducted at a normal resting cardiac output (5 to 6 
1/min). 	It would be valuable to conduct similar 
studies at cardiac outputs of about 7.5 to 10 1/min 
to simulate excercise conditions. 
(v) All prosthetic valve manufacturers should be 
required at a minimum to perform the following in 
vitro fluid dynamic studies: 
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(a) steady and 	pulsatile flow pressure drop 
measurements 
(b) pulsatile flow regurgitation measurements 
(c) pulsatile flow visualization 
(d) leaflet motion studies (for leaflet valves only) 
(vi) Detailed in vitro fluid dynamic studies should be 
conducted on selected recovered valve prostheses. 
Such studies must include pulsatile flow velocity 
and shear stress measurments. 
